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epidemiology
Worldwide almost 400.000 cases of oesophageal cancer are diagnosed. Because of the 
poor prognosis of these patients, the number of deaths almost equals the incidence 
(over 350.000 per year). Herewith cancer of the oesophagus ranks eighth on the list of 
most common cancers and sixth on the list of cancer mortality causes. The geographic 
variability in risk is very large, more than for almost any other type of cancer [1]. The 
highest risk areas of the world are in the Asian ‘oesophageal cancer belt’ (stretching from 
Northern Iran through the Central Asian republics to North-Central China). Squamous 
cell carcinomas account for the vast majority of oesophageal cancer in these regions. 
The special personal and dietary habits of the population are the most likely aetiological 
factors [2]. In the Western world the incidence of oesophageal adenocarcinoma pre-
dominates that of squamous cell carcinoma. In most areas, oesophageal cancer is more 
common in males than in females [1]. In the Netherlands the incidence of oesophageal 
cancer is about 13/100.00 for men, and 5/100.000 for women, with approximately 1450 
newly diagnosed patients per year [3]. 
Studies constantly have shown the aetiological impact of tobacco smoking and alcohol 
abuse, particularly in combination. This strong effect of tobacco and alcohol on carcino-
genesis is primarily associated with squamous cell carcinoma. Recent studies in the USA 
have established an elevated risk of oesophageal adenocarcinoma in smokers relative 
to non-smokers. There is, however, little evidence that alcohol consumption is associ-
ated with the risk of adenocarcinoma of the oesophagus [4]. Over the last decades there 
has been a substantial increase in the incidence of oesophageal adenocarcinomas of 
the lower third of the oesophagus in Western countries (compared with only a mod-
erate increases for squamous cell carcinomas). The incidence increases at a rate that 
exceeds that of any other malignancy [5]. The increase in incidence seems to be related 
to the increased prevalence of Barrett’s oesophagus, which is presumably due to gastro-
oesophageal reflux becoming more common, perhaps as a consequence of increasing 
abdominal obesity [6-8].
.
Symptomatology & diagnoSiS
The most common presenting symptoms of oesophageal cancer are dysphagia, retros-
ternal pain, pain during food or liquid passage, weight loss, haematemesis/melaena, 
and/or anaemia. When oesophageal cancer is suspected, an upper gastrointestinal 
endoscopy with biopsy is the preferred diagnostic procedure. After the diagnosis has 
been established, the additional work-up consists of an endoscopic ultrasound in order 
to determine the depth of tumour invasion into the oesophageal wall (T-stadium) and 
to determine the presence of nodal involvement (N-stadium) [9, 10]. The presence of 
cervical lymph node is best evaluated by ultrasonography of the neck [11]. A computed 
tomography scan of the chest and upper abdomen is the best diagnostic tool to assess 
distant metastases [12]. A positron emission tomography (PET)-scan improves the se-
lection of patients with oesophageal cancer for potentially curative surgery, especially 
in stages III–IV. However, the diagnostic benefit is limited after state-of the-art staging 
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[13]. After the diagnostic work-up almost half of the patients have metastatic or irresect-
able disease.
treatment
Tumours of the oesophagus limited to the mucosa can be treated by local treatment, 
preferably endoscopic mucosal resection [14]. For tumours invading the oesophageal 
wall further than T1sm1, surgical resection is currently the mainstay of treatment if the 
tumour is resectable (T1-3N0-1M0) and the patient is fit enough to undergo major sur-
gery. For patients with nodal involvement of the coeliac axis (M1a) there are several 
treatment options. When nodal involvement is limited, and a radical resection is ex-
pected, surgery is the preferred treatment with en bloc resections of the lymph nodes 
along the lesser curvature, the left gastric artery and the coeliac axis. However, when 
the lymph nodes are enlarged in such a way that irradical surgery is to be expected, 
patients at our institution are treated with induction chemotherapy followed by surgical 
resection in case of a major response to the chemotherapy [15]. Despite the curative 
intent of an oesophageal resection, the 5-year survival after a surgical resection is still 
poor (20-25%) [16]. This is in part due to the high rate of irradical resections (25-46%) 
[17-19]. 
In an attempt to improve the poor prognosis of patients with oesophageal cancer 
several treatment strategies have been used such as neoadjuvant chemotherapy and 
preoperative chemoradiotherapy. The rationale of these strategies is to achieve tumour 
shrinkage to increase the resectability rate and to enable a microscopic radical resec-
tion, and the treatment of micrometastases, thereby improving overall survival.
For tumours growing into adjacent structures (T4-tumours), radical surgery is not pos-
sible. For selected patients definitive chemoradiation might be a valuable treatment 
option. Patients with a local regional recurrence or distant metastases often need pal-
liative therapy to treat symptoms, such as dysphagia. Placement of a self-expanding 
metal stent, external beam radiotherapy, intraluminal radiotherapy (brachytherapy) 
and chemotherapy are commonly used palliative modalities [20]. 
aimS & outlineS of thiS theSiS
The aim of this thesis was, first, to explore the use of preoperative chemoradiotherapy 
and palliative chemotherapy in the treatment of oesophageal cancer.  Furthermore, the 
effects of a chemoradiotherapy regimen on histopathological and psychological and 
social level were studied.
Chapter 2 provides a review of the literature on systemic treatment for oesophageal 
cancer. An overview is given for preoperative and postoperative chemotherapy, pre-
operative chemoradiotherapy, definitive chemoradiotherapy, and palliative chemo-
therapy.
In Chapter 3 the efficacy and safety of preoperative chemoradiotherapy consisting of 
carboplatin and paclitaxel and concurrent radiotherapy for patients with resectable oe-
sophageal cancer is studied.
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In Chapter 4 the health related quality of life up to one year after surgery, in patients 
with oesophageal cancer treated with curative intent with neoadjuvant chemoradio-
therapy consisting of the above mentioned regimen followed by oesophagectomy is 
evaluated. 
Chapter 5 describes the histopathological effects of the above mentioned chemoradio-
therapy regimen and correlates the effect of specific pathologic and clinical findings to 
overall survival.
Finally, in Chapter 6 the analysis of a phase II study evaluating the safety and efficacy 
of the combination of oxaliplatin and capecitabine in patients with metastatic or local-
regional unresectable carcinoma of the oesophagus, oesophagogastric junction, and 
cardia is given. In addition, the effect of this regimen of the patients’ well-being is evalu-
ated by performing a quality of life analysis on these patients during the treatment.
The studies described in this thesis are summarized in Chapter 7. Furthermore, poten-
tial directions for future studies are addressed.
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abStraCt
Oesophageal cancer, in particular adenocarcinomas, has shown a rapid and largely un-
explained increase in incidence in the Western world. Despite advances in diagnostic 
and surgical techniques and improved pre- and postoperative care, the prognosis of 
most of the patients is poor. The review will focus on the use of chemotherapy as part 
of multimodal treatment and for patients with metastatic disease. Randomized phase 
III trials have for the most part failed to demonstrate a survival advantage with the use 
of chemotherapy. It must be emphasized that many of these phase III trial were under-
powered and do not meet today’s standard. Recent phase II trials have suggested some 
progress when chemotherapy is incorporated into the management of patients with 
oesophageal cancer. However, confirmatory and adequately powered and designed 
phase III studies are urgently needed to improve patient outcomes and for better pal-
liation of symptoms.
introduCtion
Oesophageal cancer is a highly lethal disease, as reflected by an overall survival rate of 10 
– 20%. With world-wide almost 400,000 new patients diagnosed annually, oesophageal 
cancer is the eight most common cancer, and sixth on the list of cancer mortality causes 
[1]. The incidence varies widely according to geographical region and racial background. 
In the Western World the incidence is rising [2, 3], especially due to a rapid increase in 
the incidence of adenocarcinoma of the distal oesophagus or the oesophageal-gastric 
junction. This rising incidence is not completely well understood, but obesity, gastric 
reflux and the occurrence of Barrett’s epithelia may be contributory factors [3-5].
The majority of patients who present with complaints, such as dysphagia, has either lo-
cally advanced disease (cT2-3 N0-1M0) or already metastatic disease. A surgical resection 
is currently the preferred treatment for oesophageal cancer if a patients is fit enough to 
undergo surgery and the tumour is considered to be resectable without evidence of 
distant metastases. However, approximately 30% of operated patients, clinically con-
sidered to have resectable disease, have microscopically irradical resections performed 
on [6]. Furthermore, even after surgery with curative intent, the overall survival remains 
poor. In about two-third of the patients local recurrences and/or distant metastases are 
detected within 5 years of follow-up [7]. 
Chemotherapy together with radiotherapy and/or surgery is nowadays frequently inte-
grated in the treatment of oesophageal cancer or is used for patients with metastatic 
disease. This review will focus on the use of chemotherapy alone or as part of combined 
modality treatment in patients with oesophageal cancer. The available evidence derived 
from the literature will be discussed to answer the question whether chemotherapy can 
be considered as an integral part of standard treatment or still should be considered 
to be experimental and that its impact on survival and quality of life is unproven or 
unknown.
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preoperative and poStoperative Chemotherapy
In general, surgery is considered the mainstay of treatment for patients with resectable 
oesophageal cancer. The goal of preoperative chemotherapy is a reduction of recur-
rence from occult lymphatic and/or distant metastases with improvement of survival 
and possible tumour shrinkage with an increased resectability rate. Many phase II trials 
have been published and the combination of cisplatin and 5-fluorouracil is one of the 
most frequently used regimes. Response rates of 15-60%, with a complete pathologic 
response rate of 4-7 %, after cisplatin-based combination chemotherapy are usually re-
ported [8] and often in these studies it is concluded that compared to historical controls 
the outcome is improved after preoperative chemotherapy [9]. Patients who have an 
objective response to chemotherapy have usually a significant better survival compared 
to non-responding patients [10].
The number of randomised phase III studies comparing preoperative chemotherapy 
followed by surgery versus surgery alone is limited. Furthermore, the results of some of 
these studies are difficult to interpret for various reasons such as: only a small number of 
patients included, the used chemotherapy regime is nowadays not considered optimal 
or the results have not yet been fully published. An overview of a number of these trials 
is shown in Table 1. 
Of the 2 largest conducted studies, no survival benefit was found in the Intergroup study 
[11], while in the Medical Research Council (MRC) study [12] a significant survival benefit 
was demonstrated with the use of preoperative chemotherapy. In the Intergroup trial 
440 patients were randomised to preoperative treatment followed by surgery or surgery 
alone. Patients who had stable disease or an objective response after chemotherapy 
received also two post-operative courses of chemotherapy. The overall rate of clinical 
response (19%) to preoperative chemotherapy was surprisingly low. Survival after 2 
years was also comparable in the both treatment arms. In the MRC study 802 patients 
were randomised to receive preoperative chemotherapy followed by surgery or surgery 
alone. The response rate after chemotherapy was not reported. The 2-year survival rate 
was significantly better for patients treated with preoperative chemotherapy and the 
2-year survival rates were 43% and 34%, respectively. 
The apparent difference in outcome is difficult to explain, particularly because in both 
studies comparable chemotherapy regimens were used. Possible explanations could 
be: patient selection, the type and adherence to the chemotherapy protocol of patients, 
chance and the type of surgical resection. In the Intergroup study an oesophagectomy 
through a thoracotomy was preferred while in the MRC study both a transhiatal resec-
tion and a transthoracic oesophagectomy were considered appropriate.
In a Cochrane review the results of a number published and not published studies [13] 
comparing chemotherapy followed by surgery versus surgery alone were analysed. 
The analysis was based on 11 randomised trials including a total of 2051 patients. At 
3, 4 and 5 years an increase in survival was found for preoperative chemotherapy. The 
results were only significant at 5 years. Preoperative chemotherapy led to increased tox-
icity and mortality. Urschel and colleagues performed a meta-analysis of 11 controlled 
randomised trials including 1976 patients. Their conclusion was that neoadjuvant che-
motherapy was associated with a lower rate of oesophageal resections but a higher 
rate of complete resections. Preoperative chemotherapy did not significantly increase 
Chapter 2   
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treatment related mortality. No survival benefit was demonstrated in their analysis [14]. 
Considering the above mentioned results of the available randomised phase III stud-
ies and the reviews, the possible survival benefit, if any, of neoadjuvant-chemotherapy 
for patients with oesophageal cancer is most likely small. Furthermore, it is uncertain 
whether such a potential survival benefit outweighs the morbidity caused by this treat-
ment. A surgery only arm is therefore still considered to be appropriate in randomised 
phase III studies for patients with oesophageal cancer. 
In only a few trials the effect of postoperative chemotherapy is investigated. Ando and 
colleagues were not able to demonstrate a survival benefit in a randomised trial for 
patients with squamous cell carcinomas. In this study 105 patients were treated with 2 
courses cisplatin and vindesine and 100 patients received no adjuvant chemotherapy. 
The 5-years survival rates were 48.1% and 44.9%, respectively [15]. In a subsequent 
study 242 patients were randomised and 120 patients received two cycles of cisplatin 
and fluorouracil after surgery and 122 patients had surgery alone. Although the 5-year 
disease-free survival was significantly better with surgery followed by chemotherapy 
than with surgery alone (55% and 45% respectively), there was no difference in the 
5-year overall survival rates [16]. Earlier Pouliquen and colleagues had reported a trial in 
which 124 patients after a complete or incomplete resection were randomly assigned 
to receive no chemotherapy or chemotherapy consisting of cisplatin and fluorouracil 
[17] for duration of 6 to 8 months. No difference in survival was found and the median 
survival was 13 months in the chemotherapy group and 14 months in the surgery alone 
group.
In conclusion, there is no evidence that postoperative chemotherapy improves survival 
in patients with oesophageal carcinoma.  Another disadvantage of postoperative che-
motherapy is that after major surgery such as an oesophageal resection many patients 
do not tolerate chemotherapy and this can have a detrimental effect on the anticipated 
dose intensity.
table 1. Phase III studies of preoperative chemotherapy versus surgery alone
Author[ref ]/Year Histology No. of patients Regime Survival CT Control Significance
CT Control
Roth[63]/1988 SCC 19 20 CP/Vind/BL median 9 m 9 m n.s.
Nygaard[64]/1992 SCC 56 50 CP/BL 3-year 3% 9% n.s.
Schlag[65]/1992 SCC 22 24 CP/5FU median 10 m 10 m n.s.
Maipang[66]/1994 SCC 24 22 CP/Vind/BL median 17 m 17 m n.s.
Law[67]/1997 SCC 74 73 CP/5FU median 16.8 m 13 m n.s.
Kok[68]/1997 SCC 84 85 CP/VP 3-year 41% 17% significant
Kelsen[11]/1998 SCC/AC 213 227 CP/5FU median 14.9 m 16.1 m n.s.
Ancona[69]/2001 SCC 48 48 CP/5FU median 24 m 25 m n.s
MRC[12]/2002 SCC/AC 400 402 CP/5FU median 16.8 m 13.3 m significant
ref = reference, SCC = squamous cell carcinoma, AC = adenocarcinoma, CT = chemotherapy, CP = cisplatin, BL = bleomycin, Vind = vindesine, 5FU = 
5-fluorouracil, VP = etoposide, m = months, n.s = not significant
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preoperative Chemoradiotherapy
Preoperative chemoradiotherapy is nowadays widely used in the treatment of patients 
with potentially resectable oesophageal cancer. Theoretically, chemotherapy and 
radiotherapy can interact in several ways. Both treatment modalities may be active 
against different tumour cell populations; the chemotherapy may be effective against 
micrometastases while radiation is active locoregionally.  Moreover, chemotherapy may 
synchronise cells in a vulnerable phase for radiotherapy, decrease repopulation after 
radiotherapy and enhance reoxygenation, which is advantageous for radiotherapy [18]. 
In numerous phase II studies this concept has been tested and cisplatin and 5-fluorou-
racil combined with radiotherapy is the most frequent used regime [19-22]. The limited 
sample size of most of these studies,  the differences in patients selection criteria, the 
variations in chemoradiotherapy schemes, and the intermingling of both patients with 
resectable and unresectable tumours makes it difficult to compare these phase II stud-
ies with each other. The general conclusion that can be derived from these studies is 
that preoperative chemoradiotherapy is feasible and that those patients who achieve 
a complete pathologic response have a better overall survival than those who do not 
achieve a complete response. In some of these phase II studies historical controls are 
used to estimate the effect on survival and this carries the risk that the treatment effects 
may be overestimated [23].
Surprisingly few phase III studies have been reported in which preoperative chemo-
radiotherapy followed by surgery is compared with surgery alone. In Table 2 we have 
summarised a number of the published randomised trials. Only in the Walsh study a 
significant survival benefit was found [24]. The small sample size, short follow-up, early 
stoppage based on interim analysis, disproportionate number of patients withdrawn 
from the combined modality arm, and lack of stratification based on pretreatment stage 
are some of the concerns regarding the results of this trial. 
Three meta-analyses have been published in which the effect of preoperative chemo-
radiotherapy on survival and treatment mortality was studied. Fiorica and colleagues 
included six randomised studies in their meta-analysis including 764 patients [25]. They 
table 2. Phase III  trials of chemoradiotherapy plus surgery versus surgery alone
Author[ref ]/Year Histology No.ofpatients CT RT(totaldose) Mediansurvivalinmonths
(3-year)
Significance
CRT Control CRT Control
Nygaard[64]1992 SCC 53 50 CP/BL 35Gy 8.2(17%) 7.6(9%) n.s.
Apinop[70]1994 SCC 35 34 CP/5FU 40Gy 9.7(26%) 7.4(20%) n.s.
LePrise[71]1994 SCC 41 45 CP/5FU 20Gy 10(19.2%) 11(13.2%) n.s.
Bosset[72]1997 SCC 143 139 CP 2x18.5Gy 18.6(39%) 18.6(37%) n.s.
Walsh[24]1996 AC 58 55 CP/5FU 40Gy 16(32%) 11(6%) P=0.01
Urba[73]2001 SCC/AC 50 50 CP/5FU/VBL 45Gy 16.9(30%) 17.6(16%) n.s.
ref= reference, CRT = chemoradiotherapy, CT = chemotherapy, RT = radiotherapy, SCC = squamous cell carcinoma, AC = adenocarcinoma, CP = 
cisplatin, 5FU = 5-fluorouracil, BL = bleomycin, VBL = vinblastin, n.s. = not significant
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found that chemoradiotherapy plus surgery compared with surgery alone significantly 
reduced the three-year mortality rate. However, postoperative mortality was signifi-
cantly increased by preoperative chemoradiotherapy. The significant effect on survival 
was lost when the Walsh study was excluded from the analysis. Kaklamanos and col-
leagues performed a meta-analysis on five randomised studies. The 2-year survival was 
6.4% better in the group of patients who received preoperative chemotherapy, but no 
statistical significance was reached [26]. Treatment mortality increased by 3.4% with 
chemoradiotherapy (95% CI, -.1% - 7.3%) compared to surgery alone. Urschel and col-
leagues analysed 9 randomised trials comparing neoadjuvant chemoradiotherapy and 
surgery to surgery alone for resectable oesophageal cancer [27]. Three of these nine 
studies were only published in abstract form. Survival of the two patient groups was 
similar at one and two years, but the 3-year survival was significantly higher in the group 
of patients treated with preoperative chemoradiotherapy. A flaw of these meta-analyses 
is that studies were included with study designs, treatment regimes and staging proce-
dures, which are not longer considered optimal by today’s standards. 
An alternative trial design was used in a French study. Patients who had a response 
to preoperative chemoradiotherapy were randomised between continuing chemora-
diotherapy or surgery [28]. A total of 259 patients were randomised and no significant 
difference in the 2-year survival was observed between these two groups.  A more 
or less similar design was followed in a German multicenter study. In this study 177 
patients with squamous cell carcinoma of the oesophagus were treated with 3 cycles 
chemotherapy consisting of 5-fluorouracil, leucovorin, etoposide and cisplatin followed 
by chemoradiotherapy (cisplatin, etoposide and 40 Gy radiotherapy) followed by sur-
gery or definitive chemoradiotherapy [29]. There was no statistical difference in median 
survival and 3-year survival between both groups. Although longer follow-up is needed 
and the definitive publications have to be awaited, such approaches question the role 
of additional surgery in at least those patients who respond to chemoradiotherapy. 
Positron emission tomography allows early identification of non-responding patients to 
chemoradiotherapy and could probably be helpful in the decision whether the patient 
should continue chemoradiotherapy or should be operated on [30-32]. In a systematic 
review of 12 studies positron emission tomography as a diagnostic tool in preopera-
tive staging had a moderate sensitivity and specificity for the detection of locoregional 
lymph node metastases, and a reasonable sensitivity and specificity for the detection 
of haematogenous metastases. Thus the role of positron emission tomography in the 
initial work-up of patients with oesophageal cancer is debatable [33]. 
In a number of phase I and II studies newer chemotherapeutic agent such as paclitaxel, 
docetaxel, irinotecan or biologicals have been combined with cisplatin or carboplatin 
and concurrent radiotherapy [34-37]. Although the results of these studies are encour-
aging the efficacy of these treatments has to be confirmed in randomised phase III stud-
ies. 
Many questions remain concerning the optimal radiation dose and schedule and 
chemotherapy regime. In a number of patients organ preservation might be possible, 
thereby avoiding unnecessary additional surgery, although the appropriate selection 
criteria to identify such a subgroup of patients are still lacking.
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definitive Chemoradiotherapy
Patients with potentially resectable oesophageal cancer but not considered fit enough 
for major surgery are often treated with radiotherapy alone or definitive chemoradio-
therapy. Unfortunately, the results of radiotherapy alone in the treatment of patients 
with oesophageal cancer are poor. Even with high-dose radiotherapy, failure at the pri-
mary tumour site is frequent up to 60 – 80% [38] and only a small number of patients 
treated with high-dose radiotherapy survive 5 years or longer. Chemotherapy is often 
added to radiotherapy with the aim of improving local control and survival. In more than 
a dozen randomised studies radiotherapy alone is compared with chemoradiotherapy. 
An overview of these studies is listed in Tables 3 and 4. No firm conclusions can be de-
rived from the majority of these studies for the same reasons concerning study design 
as is the case with the studies in preoperative chemotherapy or chemoradiotherapy. 
Furthermore, in a number of studies patients were included with both resectable and 
not resectable tumours.
The Radiation Therapy Oncology Group (RTOG) 85-01 study is one the most frequently 
cited studies wherein radiotherapy combined with 2 courses of 5-fluorouracil and cis-
platin followed by 2 additional courses was compared with radiotherapy alone [39]. The 
results of an interim analysis revealed statistically significant survival difference in favour 
of the chemoradiotherapy arm (median survival 12.5 months versus 8.9 months) which 
led to early closure of this study. In the RTOG 94-05 study patients were randomised to 
receive the same chemoradiotherapy regime as was used in the RTOG 85-01 study or 
the same chemotherapy regime combined with a higher dose of radiotherapy (64.8 Gy) 
[40]. After an interim analysis the trial was closed prematurely because of a high number 
of treatment related deaths in the high-dose radiotherapy arm. There was no significant 
difference in median or 2-year survival between the 2 arms. A randomised trial involving 
a total of 221 patients consisting of split-course radiotherapy with or without 2 courses 
cisplatin given 3 or 4 days before the start of radiotherapy and 4 courses afterwards was 
performed by the EORTC [41]. No significant difference in overall survival was found, 
table 3. Phase III trials of sequential chemoradiotherapy versus radiotherapy alone as definitive treatment in patients with oesophageal cancer
Author[ref ]/Year Histology No. of patients CT RT(total dose) One-year survival (%) Significance
CRT Control CRT Control
Roussel[74]1989 SCC 84 86 MTX 40.5 Gy +15.75 Gy 
boost
31 35 n.s.
Zhou[75]1991 32 32 CP/5FU 65-75 Gy 77 33 significant
Hishikawa[76]1991 SCC 24 25 Futrafur 50-70 Gy  ± 
brachytherapy
n.s.
Hatlevoll[77]1992 SCC 46 51 CP/BL 2 x 18.5 Gy 18 29 n.s.
Lu[78]1995 30            30 A/CP/5FU RT 60-70 GyCRT 
50 Gy
63 37 significant
CRT=chemoradiotherapy, CT= chemotherapy, RT= radiotherapy, SCC=squamous cell carcinoma, MTX= methotrexate, CP=cisplatin, 5FU=5-
fluorouracil, BL=bleomycin, A=doxorubicin, n.s.=not significant
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although the median time to local progression was in favour of the chemoradiotherapy 
arm.
A Cochrane Database Systematic Review has been published in which the effectiveness 
of chemoradiotherapy versus radiotherapy alone in the outcome of patients with loca-
lised oesophageal cancer was evaluated [42]. Thirteen randomised trials were included, 
with either concomitant (8) or sequential (5) chemoradiotherapy. Patients who were 
treated with concurrent chemoradiotherapy had a better survival compared to those 
treated with radiotherapy alone (reduction of one- and two-years mortality rate of 9% 
and 8% respectively). However chemoradiotherapy was associated with significantly 
more toxicity than radiotherapy alone. No studies can be found comparing definitive 
chemoradiotherapy with surgery alone.
There are several approaches to improve the results of chemoradiotherapy. By the use 
of newer chemotherapeutic agents such as the taxanes and irinotecan, weekly or con-
tinuous administration of chemotherapy together with concurrent radiotherapy, hyper-
fractionated radiotherapy schedules, better treatment results are possibly obtained [34-
37]. Targeted therapy with a cyclooxygenase-2 (COX-2) inhibitors or epidermal growth 
factor receptor (EGFR) blocking antibodies are attractive agents for combining with 
radiotherapy alone or with chemoradiotherapy. Phase 1 studies with the combination 
of chemoradiotherapy therapy and celecoxib for patients with unresectable oesopha-
geal carcinoma are underway [43, 44]. In a phase III trial patients with locoregionally 
advanced squamous cell carcinoma of the head and neck were randomised to receive 
radiation alone, or radiation plus weekly cetuximab [45]. A statistically significant pro-
longation in overall survival was found (median survival was 28 months for patients 
treated with radiotherapy only and 54 months with cetuximab and radiation), with only 
a minimal increase in overall toxicity. This is a promising approach that should also be 
table 4. Phase III trials of concurrent chemoradiotherapy versus radiotherapy alone as definitive treatment in patients with oesophageal cancer
Author[ref ]/Year Histology No. of patients CT RT One-year survival (%) Significance
CRT Control CRT Control
Earle[79]1980 SCC 47 44 BL 50-60 Gy 22 32 n.s.
Zhang[80]1984 SCC/AC 48 51 BL 39-73 Gy 
(mean 63.5Gy)
n.s.
Andersen[81]1984 SCC 40 42 BL 55-60 Gy  
Araujo[82]1991 SCC 28 31 5FU/MMC/
BL
50 Gy / 25 fr 64 55 n.s.
Roussel[83]1994 SCC 110 111 CP 40 Gy 47 31 significant
Kaneta[84]1997 SCC 12 12 CP 70-72 Gy 40 24 n.s.
Slabber[85]1998 SCC 34 36 CP/5FU 40 Gy 28 20 n.s.
Cooper[86]1999   SCC/AC 61 62 CP/5FU 50 – 64 Gy 52 34 significant
CRT=chemoradiotherapy, CT= chemotherapy, RT=radiotherapy, SCC=squamous cell carcinoma, AC=adenocarcinoma, BL=bleomycin, 5FU=5-
fluorouracil, MMC= mitomycin-C, CP=cisplatin
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explored in other epithelial malignancies demonstrating overexpression of EGFR, such 
as oesophageal cancer.
In conclusion, patients with potentially resectable oesophageal cancer, but poor can-
didates for surgery can be treated with concurrent chemoradiotherapy. Concurrent 
chemoradiotherapy leads to a modest gain in overall survival compared to radiotherapy 
alone at the cost of increased treatment related toxicity. The radiosensitizing effect of 
biologicals needs to be further explored.
palliative Chemotherapy
Improving or maintaining quality of live and symptom relief are important treatment 
goals in the management of patients with metastatic oesophageal cancer perhaps even 
more important than some prolongation of survival. Dysphagia is one of the most com-
mon symptoms and although chemotherapy can to some extent alleviate dysphagia 
[46, 47], most patients are palliated by selfexpanding metal stent placement or external 
beam radiation or brachytherapy [48].
The most frequently used chemotherapy regimen for patients with metastatic disease 
is a combination of 5-fluorouracil and cisplatin with response rates ranging from 15% to 
45% [49]. In the last years agents, such as taxanes and irinotecan, have been tested as a 
single agent or in combination with cisplatin with encouraging response rates [50, 51].
The variation in results reported in several phase II studies, even when the same agent 
or combinations are used, is most probably due to both patient and disease charac-
teristics of the treated patients. Polee and colleagues analysed prognostic factors in 
patients with advanced oesophageal cancer treated with cisplatin-based combination 
chemotherapy [52]. In a multivariate analysis performance status, serum lactate dehy-
drogenase and extent of disease were significant prognostic factors. The median surviv-
als of patients with 0, 1, 2 and 3 risk factors were 12, 8, 6 and 4 months respectively. In 
a multivariate prognostic factor analysis performed in a group of 1080 patients with 
advanced and metastatic oesophagogastric cancer enrolled into three randomised tri-
als, performance status, the presence of liver and/or peritoneal metastases, and serum 
alkaline phosphatase were identified as significant prognostic factors [53]. Patients with 
no risk factors had a better survival than patients with one or two risk factors (median 
survival 11.8 and 7.4 months respectively). Patients with three or four risk factors had 
the worst prognosis (median survival of 4 months). There were no survival differences 
among patients with oesophageal, oesophagogastric junction, or gastric cancers, 296, 
248 and 512 patients, respectively. 
We were able to identify seven randomised chemotherapy trials for patients with 
metastatic oesophageal cancer [54-61]. In the study of Nicolaou and colleagues [54] 
patients were randomised to tube insertion versus tube insertion with chemotherapy 
(cyclophosphamide and doxorubicin). Only 24 patients were included in this pilot study, 
so no meaningful conclusions can be drawn. Levard and colleagues randomised 156 
patients to chemotherapy with 5-fluorouracil and cisplatin versus no treatment [55]. 
No difference in survival was found between both arms. However, only 14 patients had 
metastatic disease and the other patients were randomised after a complete resection 
of the tumour but with lymph node involvement, an incomplete resection of the tu-
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mour or had irresectable disease. In a randomized phase II study reported by Bleiberg 
and colleagues patients with squamous cell carcinoma of the oesophagus were ran-
domised to treatment with 5-fluorouracil and cisplatin or cisplatin alone [56]. A higher 
response rate and more severe side-effects were reported for the combination arm. No 
survival difference between both treatment arms was found but, noteworthy, the study 
was not powered to detect a meaningful difference in survival. In the study reported 
by Ezdinli 63 patients treated with either doxorubicin, methotrexate or 5-fluorouracil 
[57]. Median survival was 8.1, 13.7 and 23 weeks respectively. A substantial number of 
patients dropped out after randomisation. 
In the three larger studies patients with oesophageal and gastric cancer were included. 
Webb and colleagues conducted a prospective randomised trial comparing combina-
tion chemotherapy with epirubicin, cisplatin and 5-fluorouracil (ECF) with a regimen 
consisting of 5-fluorouracil, doxorubicin and methotrexate (FAMTX) [58, 59]. Of the 256 
eligible patients 51 had oesophageal cancer, 60 cancer of the oesophagogastric junc-
tion and 145 gastric cancer. The ECF regimen resulted in a survival advantage, 8.9 versus 
5.7 months, with tolerable toxicity and better quality of life compared with the FAMTX 
regimen. In the study of Ross and colleagues ECF was compared with mitomycin, cispla-
tin and 5-fluorouracil  in 580 patients with oesophagogastric cancer including 188 pa-
tients with oesophageal cancer and 125 with cancer of the oesophagogastric junction 
[60]. Equivalent efficacy was found, but quality of life was superior with ECF. Tebbut and 
colleagues compared protracted venous infusion of 5-fluorouracil with mitomycin with 
protracted venous infusion of 5-fluorouracil alone in 254 patients with cancer involving 
the oesophagus (56 patients), oesophagogastric junction (63 patients) or stomach (131) 
[61]. The median age of patients was high (72 years) and the overall response rate was 
low (19.1% versus 16.1%), but more than 64% of the patients had improvement in pain 
control, weight loss, dysphagia, or oesophageal reflux. 
In summary in 2 trials a significant effect of chemotherapy on quality of life and/or over-
all survival was demonstrated [58, 60]. In both of these trials patients with oesophageal 
and gastric cancer, predominantly adenocarcinomas, were treated. Whether newer 
agents such as the taxanes, irinotecan, oxaliplatin, oral fluoropyrimidines and biologi-
cals will have an additive positive effect on symptom relief, quality of life and survival 
needs further investigation. 
ConCluSionS
Over the years much effort has been put in initiating and conducting studies with che-
motherapy alone or combined with other modalities for patients with oesophageal 
cancer. Most of these studies are feasibility studies, phase II studies and underpowered 
phase III studies. Unfortunately, there are more reviews published of the management 
of oesophageal cancer than there are publications about phase III trials and only a lim-
ited number of patients are entered in trials. Munro estimated that of the 6.4 million 
people that developed oesophageal cancer during 1973 and 1995 only data of 4388 
patients were included in systematic reviews [62].
What we have learnt until now is that it is feasible to administer chemotherapy preop-
eratively with or without radiotherapy or to combine chemotherapy with radiotherapy 
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as definitive treatment. For patients with metastatic disease patient characteristics 
such as performance status, extent of disease and elevated levels of serum alkaline 
phosphatase or lactate dehydrogenase are important prognostic factors when these 
patients are treated with chemotherapy [52, 53]. There are some indications that preop-
erative chemotherapy or preoperative chemoradiotherapy may have some impact on 
survival but the precise extent, if any, is still unknown and also whether it outweighs the 
increased treatment related toxicity [13, 25]. The evidence that chemotherapy may be 
beneficial for patients with metastatic disease can only be derived from 2 trials in which 
both patients with oesophageal and gastric cancer were treated [58, 60]. 
The results of chemoradiotherapy regimes with the use of newer chemotherapeutic 
agents and an increase in radiation dose and dose intensity look promising and the 
incorporation of biologicals in the management of patients with oesophageal cancer 
needs further investigation. The key issue is however that we need more well designed, 
adequately powered, randomised trials.
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abStraCt
This study was performed to assess the efficacy and safety of preoperative chemoradia-
tion consisting of carboplatin and paclitaxel and concurrent radiotherapy for patients 
with resectable (T2-3N0-1M0) oesophageal cancer. Treatment consisted of paclitaxel 50 
mg/m2 and carboplatin AUC=2 on day 1,8,15, 22 and 29 and concurrent radiotherapy 
(41.4 Gy in 23 fractions, 5 days per week), followed by oesophagectomy. All 54 entered 
patients completed the chemoradiation without delay or dose-reduction. Grade 3-4 
toxicities were: neutropenia 15%, thrombocytopenia 2%, and oesophagitis 7.5%. After 
completion of the chemoradiotherapy 63% had a major endoscopical response. Fifty-
two patients (96%) underwent a resection. The postoperative mortality rate was 7.7%. 
All patients had an R0-resection. The pathological complete response rate was 25%, and 
an additional 36.5% had less than 10% vital residual tumour cells. At a median follow-up 
of 23.2 months, the median survival time has not yet been reached. The probability of 
disease-free survival after 30 months was 60%.
In conclusion, weekly neoadjuvant paclitaxel and carboplatin with concurrent radio-
therapy is a very tolerable regimen and can be given on an outpatient basis. It achieves 
considerable down staging and a subsequent 100% radical resection rate in this series. 
A phase III trial with this regimen is now ongoing.
introduCtion
The prognosis of oesophageal cancer is poor in symptomatic patients, e.g. those with 
dysphagia. At the time of first diagnosis, almost half of such patients already have 
metastatic disease; the other half usually has locally advanced disease (T3N0 or T3N1). 
Furthermore, although surgical resection is still first choice of treatment for fit patients 
with resectable disease, most of these patients have a poor outcome. This is reflected 
by a 5-year survival rate of approximately 20 percent [1]. Despite the routine use of 
staging procedures such as Computed Tomography (CT), Magnetic Resolution Imaging 
(MRI) and Endoscopic Ultrasound (EUS), many oesophageal tumours are incompletely 
resected [2]. In a number of large randomized studies, the percentage of incomplete 
resections varied between 25 and 46 percent [3-5]. Hulscher et al. found an incomplete 
resection rate of 25% in extended transthoracic surgery versus 29% in limited transhi-
atal resection for adenocarcinoma of the oesophagus. In the study performed by the 
Medical Research Counsel, resection was microscopically complete (R0) in 60% when 
surgery was preceded by chemotherapy, and 54% in the surgery alone group. Kelsen et 
al. found incomplete resections in 14% of the patients when surgery was preceded by 
chemotherapy versus 30% for surgery alone.
Preoperative chemoradiotherapy may induce considerable tumour shrinkage and 
thereby increase the number of radical resections. In this setting, concurrent chemora-
diotherapy with 5-fluorouracil (5-FU) and cisplatin is one of the most commonly used 
regimens. Unfortunately, the impact of preoperative chemoradiotherapy with 5-FU and 
cisplatin on survival is uncertain. An improved 3-year survival was shown in three meta-
analyses of randomized controlled trials comparing neoadjuvant chemoradiotherapy 
and surgery to surgery alone [6-8], but if the study by Walsh et al [9] is excluded, this 
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benefit is lost. Furthermore, chemoradiotherapy with 5-FU and cisplatin can induce se-
vere toxicity and most patients have to be hospitalized for this treatment. Thus, the best 
regimen of preoperative chemoradiation has not yet been established.
Recently, studies with radiotherapy combined with paclitaxel with or without cispla-
tin or carboplatin have shown promising results in other tumour types. Paclitaxel is a 
microtubule-stabilizing agent that blocks the cell cycle in the G2 and M phase, the most 
radiosensitive phase. The radioenhancing effects of paclitaxel have been demonstrated 
in vitro in a human leukaemic cell line and in cell lines of squamous cell carcinoma and 
astrocytoma [10-12]. Besides its radiosensitizing effect, it also enhances the result of 
radiotherapy by increasing apoptosis and tumour reoxygenation. A weekly schedule 
permits an increase in dose-intensity and can provide continuous radiosensitizing 
plasma drug levels.
The combination of paclitaxel and carboplatin with concurrent radiotherapy has been 
tested in patients with advanced non-small-cell lung cancer. In five phase II studies, the 
combination of paclitaxel and carboplatin was given weekly with concurrent radio-
therapy, followed by two or four 21-day cycles of consolidation chemotherapy [13-17]. 
The overall response rate varied from 71 to 79%. The major toxicity was oesophagitis. 
In 10-46% of the patients a grade three or four oesophagitis was found. Treatment with 
paclitaxel and carboplatin and concurrent radiotherapy can be given on an outpatient 
basis, which is advantageous. Furthermore, this regimen is probably less toxic than cis-
platin based therapy.
On the basis of these considerations, we initiated a phase II study to determine the 
response rate and toxicity of a preoperative chemoradiotherapy regimen consisting of 
carboplatin and paclitaxel with concurrent radiotherapy in patients with a potentially 
resectable carcinoma of the oesophagus.
methodS
Eligibility criteria
Patients with histologically proven squamous cell carcinoma, adenocarcinoma, or un-
differentiated carcinoma of the oesophagus with the upper border at least 3 cm below 
the upper oesophageal sphincter were included. Disease was limited to T1N1 or T2-3N0-
1M0 tumours. Tumours extending below the gastro-oesophageal (GE) junction into the 
proximal stomach were also eligible, provided that the bulk of the tumour was located 
in the oesophagus. The longitudinal tumour length had to be ≤ 8 cm and the radial 
tumour length ≤ 5 cm. Patients were required to be aged 18 to 75 years and to have an 
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. Other criteria 
included adequate haematological, renal, hepatic and pulmonary functions as defined 
by: a granulocyte count of at least 1,500/mm3 and a platelet count 100,000/mm3; a serum 
creatinine level < 120 µmol/l and a bilirubin level ≤1.5x upper normal limit; and a forced 
expiratory volume in one second (FEV1) of at least 1.2 L. The Medical Ethics Committee 
of Erasmus University Medical Centre approved the study. Written informed consent 
was required. No previous chemotherapy and radiotherapy or a past or current history 
of malignancy other than entry diagnosis was allowed, except for non-melanomatous 
skin cancer, curatively treated carcinoma in situ of the cervix, or a “cured” malignancy 
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more than five years prior to enrolment. Patients were not eligible if they had lost more 
than 10% of their body weight or had an inadequate caloric- and/or fluid intake.
Staging
Pre-treatment evaluation included a detailed history taking, a physical examination and 
a routine complete blood work-up. All patients underwent a baseline upper gastroin-
testinal (GI) endoscopy and EUS, and a CT of the chest and the upper abdomen, plus 
ultrasonography of the neck and pulmonary function tests. 
Treatment
Chemotherapy
Paclitaxel 50 mg/m2 and Carboplatin targeted at an AUC of 2 were administered on days 
1, 8, 15, 22 and 29. All patients received dexamethasone 10 mg, clemastine 2 mg and 
ranitidine 50 mg, administered intravenously 30 minutes prior to paclitaxel infusion. 
Paclitaxel was given as a 1-hour infusion diluted in 500 mL of sterile and isotonic so-
dium chloride solution (saline). After the completion of the paclitaxel infusion, 100 mL 
of saline was infused over 30 minutes followed by an infusion of 8 mg ondansetron or 
its equivalent diluted in 100 mL of saline given over 30 minutes. Hereafter, the total 
calculated dose of carboplatin diluted in 500 mL of 5% dextrose solution was adminis-
tered over 1-hour. Dose modifications were made for toxicity, using the National Cancer 
Institute - Common Toxicity Criteria (NCI-CTC version 2). 
Radiotherapy
All patients were irradiated by external beam radiation, using a 3-D conformal radiation 
technique. The Gross Tumour Volume (GTV) was defined by the primary tumour and any 
enlarged regional lymph nodes, and was drawn on each relevant CT slice. The Planning 
Target Volume (PTV) provided a 1.5 cm radial margin and a proximal and distal margin 
of 4 cm around the GTV. If the tumour extended into the stomach, a distal margin of 3 
cm was chosen. Before the start of the irradiation, a planning CT scan was made from 
the cricoid to L1 vertebra with a slice thickness of ≤ 5 mm, with the patient in treatment 
position. Beams-eye-view (BEV) was used to ensure optimal target volume coverage 
and optimal normal tissue sparing. The prescription dose was specified at the ICRU 
50/62 reference point, which was the isocenter for most patients. The daily prescription 
dose was 1.8 Gy at the ICRU reference point and the 95% isodose had to encompass 
the entire planning target volume (PTV). The maximum to the PTV was not allowed to 
exceed the prescription dose by >7% (ICRU 50/62) guidelines. Tissue density inhomo-
geneity correction was used. Portal images were obtained during the first fraction of 
all fields. A total dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, with 5 fractions per 
week starting on the first day of the first cycle of chemotherapy. 
Surgery
Surgery was planned within six weeks after the completion of the chemoradiation. 
For carcinomas located distally of the tracheal bifurcation, a transhiatal oesophageal 
resection was favoured. For carcinomas located proximally to the tracheal bifurcation, 
a transthoracic oesophageal resection was performed. In both techniques, a wide local 
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excision including the N1 lymph nodes was carried out, including a standard resection 
of the lymph nodes around left gastric artery. The continuity of the digestive tract was 
restored by means of a gastric tube reconstruction with an anastomosis in the neck. 
Pathological Analysis
The resection specimen was evaluated using a standard protocol, providing information 
on margins, tumour type, extension of the tumour, and lymph nodes. The 6th edition of 
the International Union Against Cancer (UICC) was used for TNM-classification, tumour 
grade, and stage grouping [18]. When no tumour tissue could be seen, lesions such as 
an ulcer or an irregular area covered by mucosa were embedded in total together with 
surrounding areas in order to adequately judge the presence of residual tumour and 
therapy effects. The grading of the therapy response was performed as described by 
Junker et al. [19]. The degree of histomorphological regression, i.e. the effect of chemo-
radiation, was classified into four categories: grade I: more than 50% vital residual tu-
mour cells; grade II: 10-50% vital residual tumour; grade III: less than 10% vital residual 
tumour cells; grade IV: complete tumour regression, no evidence of vital tumour cells.
A two-field lymph node dissection was carried out containing regional (mediastinal, 
oesophageal) and distant sites (coeliac region). The resection margins, especially the 
circumferential margin, were evaluated with a 1 mm cut-off point for vital tumour, im-
plying that the tumour-free margin is >1mm. If vital tumour was present at ≤ 1mm from 
the surgical resection margin it was considered positive.
Restaging and follow-up
Upper GI endoscopy and CT of the chest and upper abdomen were repeated after the 
completion of the chemoradiation and ahead of the planned operation. Pulmonary 
function tests were repeated six and twelve months after therapy. Follow-up visit were 
performed every three months during the first 2 years and every 6 months thereafter 
to document late toxic effects, and, if applicable, disease relapse or progression, and 
death. 
Statistical Analysis
As the statistical design was intended to allow us to detect a response percentage of at 
least 40%, it was calculated that 50 patients were needed. The pathological response to 
chemoradiation was defined as mentioned above. The response to chemoradiotherapy 
evaluated by endoscopy was classified as either no response, less than 50 per cent re-
sponse, more than 50 per cent response, or complete response. These broad classifica-
tions were used in an attempt to reduce inter-observer variation [20]. Tumour response 
evaluated by radiology was assessed according to the Response Evaluation Criteria In 
Solid Tumours (RECIST) [21].
Survival time was calculated as the duration from the day of start of chemoradiotherapy 
to death or the last follow-up, and recurrence-free interval was calculated from the day 
of surgery to the day of diagnosis of recurrence. Overall and disease-free survivals were 
estimated using the Kaplan-Meier method. Median survival time was obtained from the 
time corresponding to 50% survival based on the Kaplan-Meier survival curve.
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reSultS
Patient Characteristics
Fifty-four eligible patients were enrolled between February 2001 and January 2004. 
Written informed consent was obtained from all patients. Characteristics of these 54 
patients are summarized in Table 1. Ninety-one percent of patients were male and 76% 
table 1. Patient Characteristics
Characteristic number (%)
Total number of patients 54
Sex
 Male 49 (91)
 Female 5 (9)
Age (years)
 Median 59
 Range 40-75
Performance status (ECOG)
 0 35 (65)
 1 18 (33)
 Unknown 1(2)
Weight loss (%)*
 Median 2
 Range 0-12
Histology
 Adenocarcinoma 41 (76)
 Squamous cell carcinoma 12 (22)
 Large cell carcinoma 1(2)
Barrett’s oesophagus@
 Yes 19 (46)
 No 17 (42)
 Unknown 5 (12)
Stage (EUS)
 T2N0 5 (9)
 T2N1 2 (4)
 T3N0 18 (33)
 T3N1 21 (39)
 No pass 8 (15)
Primary site
 Thoracic oesophagus 5 (9)
 Lower oesophagus 49 (91)
*calculated from the data of 52 patients
@calculated in 41 patients with adenocarcinoma. Yes=Barrett’s oesophagus identified by upper endoscopy and confirmed by histopathologic 
examination. No=No Barrett’s oesophagus identified by upper endoscopy or by histopathologic examination. Uncertain=Barrett’s oesophagus 
identified by upper endoscopy or by histopathologic examination.
EUS=Endoscopic ultrasound
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had an adenocarcinoma. Of these 41 adenocarcinomas, 23 were located at the gastro-
oesophageal junction and 18 in the distal oesophagus. The patient with 12% weight 
loss was accepted for chemoradiotherapy, because the weight loss was partly due to de 
novo diagnosed diabetes mellitus.
Toxicity of and adherence to chemoradiotherapy
Fifty-three patients (98%) completed the preoperative treatment. One patient died at 
home after the second course of chemotherapy, probably due to a cardiac arrest. All other 
patients completed the neoadjuvant chemoradiotherapy as scheduled, without treatment 
delay or dose reduction. The 1.5 cm radial radiation margin was achieved in all patients, 
there were no compromises. The V20 was obtained in all patients and never exceeded 30% 
of the total lung volume. The acute toxicities due to the chemoradiation were usually mild. 
Haematological toxicity is listed in Table 2. Grade 3 or 4 toxicity consisted of leucopenia in 
13 patients (23.5%), neutropenia in eight patients (15.1%), and thrombocytopenia in one 
patient (1.9%). Two patients required a blood transfusion for anaemia (3.8%). Infectious 
complications were rare, only one patient was treated for pneumonia due to aspiration, no 
neutropenia was found. Three other patients also developed fever, but no infectious focus 
was found (see below). Relevant non-haematological toxicity (Table 3) consisted mainly of 
oesophagitis and dysphagia. Four patients (7.5%) developed grade 3 oesophagitis. Dys-
phagia improved during chemoradiation in 17 of 35 patients (48.6%), three of whom had 
initial nutritional support because of grade 3 dysphagia, which could be discontinued. 
Dysphagia worsened in nine patients (17%), three of whom required nutritional support 
because of grade 3 dysphagia. In three patients needing nutritional support before start-
ing chemoradiation the support could not be discontinued during the chemoradiation. 
Sensory neuropathy was seen in only 5 patients (9.4%), in 3 patients it resolved after com-
pletion of the chemoradiotherapy. Seven patients (13.2%) were hospitalized. Five of them 
were briefly hospitalized for placing a nasogastric tube for nutritional support, because of 
grade 3 oesophagitis or dysphagia. One also had a pulmonary embolism and fever with 
grade 3 neutropenia, one was also treated for pneumonia due to aspiration, and one pa-
tient also had fever with grade 3 neutropenia. One patient was hospitalized because of 
rectal bleeding. Colonoscopy revealed a non-malignant polyp, which was removed. One 
patient was hospitalized because of vomiting and fever with grade 2 neutropenia. 
table 2. Haematological toxicities
Grade
0 1 2 3 4
No. (%) No. (%) No. (%) No. (%) No. (%)
Anaemia 7 (13.2) 42 (79.2) 4 (7.5) - -
Leucopenia 4 (7.5) 11 (20.8) 25 (47.2) 12 (22.6) 1 (1.9)
Neutropenia 17 (32.1) 19 (35.8) 9 (17) 8 (15.1) -
Thrombocytopenia 30 (56.6) 19 (35.8) 3 (5.7) 1 (1.9) -
Data from 53 evaluable patients
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Response to chemoradiotherapy
Evaluation with upper GI endoscopy and CT was done after a mean of ten days fol-
lowing the last radiotherapy session. Response evaluation with endoscopy showed a 
complete response in ten patients (18.9%), a major response in 23 patients (43.4%), a 
minor response in 11 patients (20.8%), and no response in one patient (1.9%). In five pa-
tients response evaluation by endoscopy was not possible (in one patient there was “no 
pass”, in four patients the baseline endoscopy was performed in another hospital) and 
in three patients no endoscopy was performed after completing the chemoradiation. 
Response evaluated with CT showed no complete response or disease progression. In 
three patients (5.6%) a partial response was observed.
Surgical Results
One patient refused surgery after having completed the chemoradiotherapy. Endos-
copy in this patient revealed a complete response. After 12 months of follow-up, a local 
recurrence of the oesophageal tumour was diagnosed, further workup also revealed 
supraclavicular lymph nodes. He refused further treatment. Thirteen months later he 
died from progressive disease. A transhiatal oesophagectomy was performed in 46 of 
the 52 patients, and a transthoracic resection in 6 patients. The median time between 
the completion of chemoradiotherapy and surgery was 42 days (range 20 to 74 days). 
The in hospital postoperative mortality rate was 7.7% (CI 0-15%). Two patients died from 
systemic complications due to anastomotic leakage, one patient from a cerebral vas-
cular accident one day after surgery, and one from sepsis. Autopsy in the latter patient 
revealed a prostatitis as the probable focus of the sepsis. Postoperative complications 
were seen in 38 patients (73%). These complications were mainly pulmonary (42%) or 
cardiac (13%) (Table 4). Besides the two lethal anastomotic leaks, in 10 of the 48 (20.8%) 
patients surviving postoperatively an anastomotic leak was seen. In five of them (10.4%) 
the leakage was a radiological finding on routinely performed contrast swallow postop-
eratively. In all patients the clinical signs of the leak could be treated conservatively, but 
in two patients (4.2%) the leak resulted in long-term nutritional support. Twenty-two 
patients (45.8%) developed an anastomotic stricture requiring endoscopic dilatation 
(range 1-27, median 7). Eventually, all patients were able to eat solid food.
Pathological results
In 13 patients no residual tumour in the resected oesophagus or regional lymph nodes 
was found, corresponding to a pathological complete response (pCR) rate of 25%. The 
pathological stages of the other resection specimens were: pT1N0-1M0 in 12 patients 
table 3. Non-haematological toxicities
Grade
0 1 2 3 4
No. (%) No. (%) No. (%) No. (%) No. (%)
Nausea 15 (28.3) 35 (66) 3 (5.7) - -
Vomitus 36 (67.9) 15 (28.3) 2 (3.8) - -
Oesophagitis 11 (20.8) 23 (43.4) 15 (28.3) 4 (7.5) -
Lethargy 23 (43.4) 23 (43.4) 7 (13.2) - -
Skin toxicity 34 (64.2) 18 (34) 1 (1.9) - -
Data from 53 evaluable patients
   Neoadjuvant chemoradiation
39
(23.1%), pT2N0-1M0 in 6 patients (11.5%), pT3N0-1M0 in 16 patients (30.8%), pT0-3N0-
1M1A in 4 patients (7.7%), and pT1N1M1B in 1 patient (1.9%). In 19 patients (36.5%) 
a regression grade III, in 14 patients (26.9%) a regression grade II, and in 6 patients 
(11.5%) a histopathological regression grade I was seen. In 7 of the 18 patients (38.9%) 
with a pathological T3-stage only scattered tumour cells were found in the resection 
specimen. A radical resection with no evidence of tumour cells at the resection margins 
(R0-resection) was obtained in all patients. The lymph node dissection status showed 
a median of eight nodes (range 0-30), derived from both regional and distant sites. In 
13 patients (25%) one or more positive lymph nodes were found (median 2, range 1-6). 
The N-stage improved from N1, as assessed by EUS, to N0 postoperatively in 19 patients 
(36.5%). In 4 patients (7.7%) the N0-stage, as assessed by EUS, was changed towards a 
N1-stage postoperatively. 
Pulmonary toxicity
The post-treatment pulmonary function tests (measured 6 months and 1 year after sur-
gery) deteriorated significantly compared to the pre-treatment tests. The total lung ca-
pacity (TLC) decreased from 103 percent of the predicted value to 92 percent (p=0.002). 
The vital capacity (VC) declined from 105 percent of the predicted value to 96 percent 
(p<0.001). The forced expiratory volume in 1 second (FEV1) decreased from 94 percent 
of the predicted value to 87 percent (p<0.0001). This decline in pulmonary function 
tests did not lead to major clinical symptoms.
Survival
All 54 patients were included in the survival analysis. At the time of evaluation (May 
31, 2005) the median follow-up time for all patients was 23.5 months (range 0 to 52 
table 4. Postoperative complications
Complication Number of patients
None 14
Pulmonary 22*
 Upper airway infection 9
 Pneumonia 7
 Chylothorax 3
 Pulmonary embolism 2
 Pleural effusion 2
 Atelectasis 1
 Pleural empyema 1
 Acute respiratory distress syndrome 1
Cardiac 12
 Atrial fibrillation 10
 Decompensation cordis 2
 Asystole during intubation 1
Wound infection 5
Vocal cord paralysis 3
Other 9
Data from 52 evaluable patients
*In four patients two events
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months). The median follow-up time for surviving patients was 31 months (range 11-
52 months). Nineteen of the 54 patients (35.2%) died: 13 due to recurrent cancer, five 
during treatment (four postoperatively and one sudden death) and one due to a rup-
tured aortic aneurysm. The median survival time, however, has not yet been reached. 
The estimated 1-, 2-, and 3-year survival rates were 82%, 65%, and 56%, respectively. 
The Kaplan-Meier curve for overall survival is shown in Figure 1. The survival of patients 
with a pCR was not better than the survival of patients with no pCR. Recurrent disease 
after surgery was found in 15 patients surviving postoperatively (15/48, 31.2%). Three 
of them were still alive at the time of analysis. Recurrence was locoregional in seven 
patients. Distant metastases were found in 14 patients. The patient who refused surgery 
died from recurrent disease as well (see before). The Kaplan-Meier curve for disease free 
survival of the patients surviving postoperatively is shown in Figure 1. The patient who 
died without recurrence was censored at the time of death.
diSCuSSion
Preoperative chemoradiotherapy is nowadays widely used in the treatment of patients 
with potentially resectable oesophageal cancer. The concept that preoperative chemo-
radiotherapy may lead to a better tumour control and therefore to a better overall sur-
vival is appealing, as 29-43% incomplete resections are performed when patients are 
treated with surgery alone or with chemotherapy followed by surgery [3-5]. Many stud-
ies have reported that after chemoradiotherapy in 10-28% of the patients no tumour 
Figure 1. Kaplan-Meier survival curves
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cells are found in the resection specimen [9, 22-25]. However, surprisingly few phase 
III studies have been reported in which preoperative chemoradiotherapy followed by 
surgery was compared with surgery alone. Meta-analyses of these trials showed a small, 
if any, effect on survival [6-8]. In addition, the results of a recently reported study were 
disappointing, showing no survival benefit for those patients treated with preoperative 
chemoradiotherapy [26]. In most studies, the combination of 5-FU and cisplatin with 
radiotherapy has been applied. In our study we used paclitaxel and carboplatin with 
concurrent radiotherapy. 
Our study showed that preoperative chemoradiotherapy with weekly paclitaxel and 
carboplatin was well tolerated. All patients completed the chemoradiotherapy as 
scheduled, without treatment delay or dose reduction. The major non-haematological 
toxicity was a grade 3 or 4 oesophagitis in 7.5% of the patients. Compared to other 
studies with chemoradiotherapy in oesophageal cancer, this incidence of grade 3 and 4 
oesophagitis is low [25, 27].
The postoperative mortality of this study (7.7%; 95% CI 0-15%) was somewhat higher 
than the approximately 4% mortality rate found in other trials performed at our insti-
tution [4, 28, 29], however, the observed mortality rate still lies within the 95% con-
fidence limits. Postoperative morbidity consisted mainly of pulmonary complications. 
This high pulmonary complication rate is partly due to the fact that we also scored mi-
nor pulmonary complications, such as upper airway infections. Whether preoperative 
chemoradiotherapy is responsible for a higher pulmonary complication rate cannot be 
excluded. In a retrospective study of Avendano et al preoperative chemoradiotherapy 
was associated with an increase risk of pulmonary complications (i.e., duration of me-
chanical ventilation) [30]. Whether the decline in pulmonary function tests (TLC, VC, and 
FEV1) that we observed in our study was due to the chemoradiotherapy is uncertain, 
as it has also been reported that the TLC and the VC were significantly reduced after an 
oesophagectomy without preoperative treatment [31].
During follow-up 22 patients required dilatations because of an anastomotic stricture. 
The dilatations resolved the dysphagia in all patients, eventually all patients had an 
adequate food intake. Neoadjuvant chemoradiotherapy has not been reported to be 
associated with a higher stricture formation rate [32]. 
In this study, the overall and disease free survivals compare favourably with those in 
other trials of preoperative chemoradiation for oesophageal cancer. With a median 
follow-up of 23.5 months, the median survival time has not yet been reached. However, 
such findings should be interpreted with caution, because phase II studies always carry 
the risk of selection bias. A complete (R0) resection was accomplished in all patients, 
using a 1 mm cut-off point for circumferential resection margin and this also compares 
favourably with other studies. The pathologically complete response rate of 25% in our 
study is consistent with that in other studies using preoperative chemoradiation. A ma-
jor histomorphological regression was seen in another19 resected specimens. Thus, in a 
total of 32 patients (61.5%) a major or complete pathological response to preoperative 
chemoradiation was found. Several studies have shown that a pCR and an R0-resection 
are associated with a better prognosis [33, 34]. Surprisingly, we were not able to demon-
strate a significant survival difference between patients who had a pCR and those who 
did not have a pCR. Since all operated patients had an R0 resection, a possible adverse 
effect of an incomplete resection on survival could not be assessed. The 100% complete 
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resection rate and high number of patients with a major or complete pathological re-
sponse might explain the lack of survival benefit in patients who had a pCR. 
 In conclusion, this study shows that preoperative treatment with weekly paclitaxel 
and carboplatin with concurrent radiotherapy is well tolerated, with leucopenia and 
oesophagitis being the most common side effects. After chemoradiotherapy a high 
rate of radical resections could be achieved and the overall survival looks promising. A 
randomized phase III trial with this regimen followed by surgery versus surgery alone is 
now ongoing, which has, up to now, included more than 100 patients in the first year, to 
determine its role in the treatment of resectable oesophageal carcinoma.
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abStraCt
purpose. Because of the trade-off between the potentially negative quality of life 
(QoL) effects and the uncertain favorable survival effect of neoadjuvant chemoradio-
therapy in patients with resectable esophageal cancer, we assessed the heath-related 
QoL (HRQoL) for up to one year postoperatively in these patients, treated with preop-
erative chemoradiotherapy with a non-platinum based outpatient regimen followed by 
esophagectomy. 
methods and materials. Patients undergoing neoadjuvant paclitaxel and carboplatin 
concurrent with radiotherapy followed by surgery completed standardized HRQoL ques-
tionnaires before and after chemoradiotherapy and at regular moments up to one year 
postoperatively. We analyzed differences in generic Qol core questionnaire [QLQC30] 
and condition-specific (esophageal site-specific [OES-18]) HRQoL scores over time by 
using a linear mixed-effects model.
results. Mean scores of most HRQoL scales deteriorated significantly during neoadju-
vant chemoradiotherapy. The largest deterioration was observed for physical and role 
functioning scales. All but two symptom scores worsened significantly. 
Postoperatively, most mean HRQoL scores improved until recovery to baseline level. 
Speed of improvement varied. The average taste score returned to baseline level three 
months postoperatively, while it took one year for the average role functioning score 
to restore. The emotional functioning score showed a different pattern; it was worst at 
baseline, and increased over time during chemoradiotherapy and postoperatively. The 
dysphagia and pain scores worsened considerably during chemoradiotherapy, restored 
to baseline three months postoperatively, and were even significantly better one year 
postoperatively.
Conclusions. Preoperative chemoradiotherapy with paclitaxel and carboplatin for 
resectable esophageal cancer had a considerable temporary negative effect on most 
aspects of HRQoL. Nonetheless, all HRQoL scores were restored or even improved one 
year postoperatively.
introduCtion
Esophageal cancer is a devastating disease. Many patients, who present with dysphagia, 
already have irresectable and/or metastatic disease at the time of diagnosis. For those 
patients with assumingly resectable disease, who are fit enough to undergo a major 
surgical procedure, esophagectomy is the preferred treatment. However, esophageal 
surgery is associated with considerable peri-operative morbidity and mortality, espe-
cially in low-volume hospitals [1]. Apart from the severe physical impact, an esophageal 
resection and the underlying disease also have major psychological and social effects. 
Studies in patients who underwent an esophageal resection for esophageal cancer have 
shown a decrease in quality of life (QoL) following an esophagectomy. Health-related 
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QoL (HRQoL) scores are usually restored to baseline values within six to nine months 
after surgery [2-5]. 
The 5-year survival after an esophageal resection is approximately 20% [6]. Because of 
this poor outcome of surgery alone, many patients are nowadays treated with multi-
modality treatment including preoperative chemoradiotherapy (CRT). An advantage of 
neoadjuvant CRT may be an increase in the radical resection rate, thereby improving the 
overall survival. In most phase III studies a positive effect of neoadjuvant CRT on overall 
survival could not be demonstrated, albeit that in most studies only a small number of 
patients were included and that most studies had methodological flaws considered by 
today’s standards. Meta-analyses of these studies, on the contrary, suggest a positive 
effect on overall survival [7].
Whether neoadjuvant CRT leads to a decreased HRQoL during treatment or leads to an 
impaired and/or delayed recovery of HRQoL after surgery is not well known. Only two 
papers have addressed this issue [8, 9]. HRQoL analyses are especially important now 
that neoadjuvant CRT is being increasingly used, because in this situation a negative 
impact on HRQoL outweighs an uncertain therapeutic benefit.
The aim of this prospective study was to evaluate the HRQoL up to one year after surgery 
in patients with esophageal cancer treated with curative intent by neoadjuvant CRT with 
a non-platinum based outpatient regimen followed by esophagectomy. This study 
adds to the previously published ones, because we used a different CRT regimen (carbopla-
tin and paclitaxel concurrent with radiotherapy). Furthermore, post-CRT HRQoL was mea-
sured within one week after finishing CRT, at which time-point toxicity is usually highest.
methodS and materialS
Between February 2001 and January 2004 patients with resectable esophageal cancer 
were asked to participate in a phase II study to determine the response rate and toxicity of 
a preoperative CRT regimen, consisting of weekly administrations of carboplatin and pa-
clitaxel and concurrent radiotherapy. The details of this study were described elsewhere 
[10]. Patients who participated in this study were asked to fill in HRQoL questionnaires. 
Written informed consent was obtained from all patients. The Medical Ethics Committee 
of Erasmus University Medical Centre, The Netherlands, approved the study.
Treatment
After staging with endosonographic ultrasound, computed tomography of the chest 
and upper abdomen, and ultrasonography of the neck, patients with stage T1N1 or 
T2-3N0-1 were treated with paclitaxel 50 mg/m2 and carboplatin AUC 2 on days 1, 8, 
15, 22 and 29 and concurrent radiotherapy, followed by esophagectomy. Radiotherapy 
consisted of a total dose of 41.4 Gy, given in 23 fractions of 1.8 Gy, 5 fractions per week 
starting on the first day of the first cycle of chemotherapy. All patients were irradiated 
by external beam radiation, using a 3-D conformal radiation technique. The gross tu-
mor volume (GTV) was defined by the primary tumor and any enlarged regional lymph 
nodes. The planning target volume (PTV) provided a 1.5 cm radial margin and a proxi-
mal and distal margin of 4 cm around the GTV. If the tumor extended into the stomach, 
a distal margin of 3 cm was chosen. 
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Quality of life measures
HRQoL was assessed with the European Organization for Research and Treatment of 
Cancer (EORTC) core questionnaire (EORTC QLQ-C30, version 3.0), and with the esopha-
geal site-specific module (OES18) [11-13]. The QLQ-C30 contains five functional scales 
(physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and 
nausea/vomiting), a global health/quality of life scale, and six single items (dyspnea, 
insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The OES18 
contains four symptom scales (dysphagia, eating, reflux, and pain) and six single items 
(trouble with saliva, choking, dry mouth, taste, cough, and speech). Dysphagia, eating, 
and pain from the OES18 questionnaire were considered disease related symptoms. The 
other symptom scales were regarded as treatment related. All scores range from 0 to 
100. A high score for a functional scale represents a high level of functioning, a high 
score for the global health/quality of life scale represent a high global QoL, but a high 
score for a symptom scale or item represents a high level of symptoms. 
Timing of assessments 
Baseline HRQoL assessments were performed before starting CRT. Follow-up data were 
collected one week after finishing CRT, and 3, 6, 9, and 12 months postoperatively. The 
patients themselves filled in the questionnaires.
Statistics
HRQoL data are presented as mean values. For the handling of missing data the EORTC 
QLQ-C30 Scoring Manual [14] was used. 
To analyze patterns of HRQoL data in time we used linear mixed-effects models [15] as 
implemented in S-plus. Time was taken as a categorical variable and patient’s identifica-
tion number as random intercept. Differences between pre-treatment baseline scores 
and follow-up measurements (after CRT, and 3, 6, 9 and 12 months after surgery) were 
tested. Significant time effects represent differences between follow-up and baseline. 
We defined the minimal important difference following common guidelines as 0.5 SD of 
the standard deviation at baseline [16]. 
To identify which scores or items had the greatest impact on the deterioration of the 
global QoL post-CRT, we performed univariate analyses of variance with global QoL as 
dependent variable and the scores and items as covariates.
We tested differences in HRQoL scores between responders and non-responders to neo-
adjuvant CRT by adding both response as such, and the interaction between response 
and time. The first analysis assumes the difference between responders and non-re-
sponders to remain the same during follow-up; the second gives information for every 
point in time, but naturally has less power to find significant differences. The distinction 
was only made after t=1. Response to CRT was defined as the presence of less than 10% 
vital residual tumor cells in the resected specimen (pathological response). 
Calculations were performed with the Statistical Package for the Social Sciences (ver-
sion 12.0; SPSS Inc., Chicago, IL, USA) and S-Plus (version 6.0 Professional Release 1, 
1988-2001; Insightful Corporation, Seattle, WA, USA).
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reSultS
During the study period, 54 patients underwent CRT. After neoadjuvant treatment, two 
patients did not proceed to esophagectomy: one patient died during the second che-
motherapy course (death unrelated to esophageal cancer or treatment) and one patient 
refused surgery. Baseline characteristics are shown in Table 1. The in-hospital mortality 
after esophagus resection was 4/52 (7.7%). Clinical outcome is shown in Table 2.
Questionnaire compliance and missing data
The compliance rate was 92.6% (50/54) at baseline for the QLQ-C30 and 90.7% (49/54) 
for the OES18. The questionnaires were all missed because of administrative errors 
(patients accidentally not handed the questionnaires or patients not completed or re-
turned the questionnaires). Numbers of questionnaires available for analysis are shown 
in Table 3. The numbers decreased over time, due to random administrative problems 
(n= 20 missed questionnaires) and patients who died. One patient died during CRT, four 
patients died postoperatively due to complications of the surgery, one patient died due 
table 1. Patient Characteristics
Characteristic number (%)
Total number of patients 54
Sex
 Male 49 (91)
 Female 5 (9)
Age (years)
 Median 59
 Range 40-75
Performance status (ECOG)
 0 35 (65)
 1 18 (33)
 Unknown 1(2)
Histology
 Adenocarcinoma 41 (76)
 Squamous cell carcinoma 12 (22)
 Large cell carcinoma 1(2)
Stage (endoscopic ultrasound)
 T2N0 5 (9)
 T2N1 2 (4)
 T3N0 18 (33)
 T3N1 21 (39)
 No pass* 8 (15)
Primary site
 Thoracic oesophagus 5 (9)
 Lower oesophagus 49 (91)
ECOG = Eastern Cooperative Oncology Group
*The probe for the endoscopic ultrasound was not able to pass the tumor
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to recurrent disease between three and six months postoperatively and another be-
tween six and nine months postoperatively, and between nine months and one year of 
follow-up two patients died due to recurrent disease and one due to an unrelated cause. 
Overall, 84% (272/324) of the QLQ-C30 and 82% (267/324) of the OES18 questionnaires 
were completed. Analyses were performed using the available data.
Health-related Quality of Life during neoadjuvant treatment
Patients reported a decrease in several aspects of HRQoL during preoperative CRT (Table 4). 
Differences between mean scores after CRT and baseline were significant and ≥ 0.5 SD (i.e. 
table 2. Clinical outcomes after esophagectomy
Characteristic no. (%)
Nasogastric tube for nutritional support
 Removed 3/6
 Placed 3/47
Weight loss during chemoradiation (kg)
 Mean 1.4
 Range -5 to +4
pTNM†
 pCR 13 (25)
 pT1N0-1M0 12 (23.1)
 pT2N0-1M0 6 (11.5)
 pT3N0-1M0 16 (30.8)
 pT3N0M1A 4 (7.7)
 pT1N1M1B 1 (1.9)
 Postoperative in-hospital mortality† 4 (7.7)
 Postoperative morbidity† 37 (73)
Hospital stay (days)†
 Median 13
 Range 8-61
Overall survival (months)‡
 Median 35
 Range 0.5-52
pTNM = pathological TNM-Stage; pCR = pathological complete response.
*calculated from the data of 53 patients
†calculated from the data of 52 patients
†† survival since start chemoradiation
table 3. Questionnaires available for HRQoL analysis
QLQ-C30 (%) OES-18 (%)
Baseline 50/54 (92.6) 49/54 (90.7)
After CRT 49/53 (92.5) 48/53 (90.6)
3 months PO 46/49 (93.9) 46/49 (93.9)
6 months PO 43/48 (89.6) 41/48 (85.4)
9 months PO 44/47 (93.6) 44/47 (93.6)
1 year PO 40/45 (88.9) 39/45 (86.7)
CRT = chemoradiotherapy; PO = postoperative; OES-18 = esophageal site-specific questionnaire; QLQ-C30 = Quality of life core questionnaire.
Values expressed as real/expected (percent).
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clinically meaningful) for most functioning scores. In Figure1 the course of the functioning 
scores during treatment and follow-up is shown. Emotional functioning scores were low at 
baseline and remained low, on average, throughout CRT. Mean scores for most treatment 
related symptoms worsened significantly, the changes exceeding 0.5 SD. In Figure 2 the 
course of the fatigue score during treatment and follow-up is shown. Nausea/vomiting, 
pain, dyspnea, and appetite loss scores showed the same pattern as the data in Figure 2. 
Local tumor symptom scores (dysphagia, eating, and pain from the OES18 questionnaire) 
deteriorated during CRT, as well. In Figure 3 the course of the dysphagia score during 
treatment and follow-up is shown. Eating and pain scores from the OES 18 questionnaire 
showed the same pattern as the data in Figure 3. Scores from items assessing sleeping, 
financial problems, reflux, and choking did not change during CRT. Global QoL decreased 
significantly and on average 17 points during neoadjuvant treatment (Figure 4).
On univariate analysis, the difference in physical functioning, role functioning, cogni-
tive functioning and fatigue between post-CRT and baseline had a significant effect on 
global QoL (p=0.035, p=0.019, p=0.03, and p=0.028, respectively).
Health-related Quality of Life after Esophagectomy
During the postoperative follow-up period, most aspects of HRQoL returned to base-
line levels (Table 4). Differences between mean scores during follow-up and baseline 
decreased and finally, the average scores returned to baseline levels for role, cognitive, 
social functioning, and global QoL scores (Figures 1 and 4). The average global QoL 
score and the average cognitive functioning score returned stored to baseline within 
three months after surgery, the average social functioning score within six months post-
Figure 1.  Mean functioning scores during treatment and follow-up. A high score is equivalent to a better quality of life. CRT = chemoradiotherapy; 
PO = postoperatively
1
50
60
70
80
90
100
baseline post-CRT 3 months PO 6 months PO 9 months PO 12 months PO
PF
RF
EF
CF
SF
PF
RF
EF
CF
SF
Physical
Role
Emotional
Cognitive
Social
M
ea
n 
Sc
or
e
Esophagectomy
Chapter 4   
52
Figure 2. Mean fatigue scores during treatment and follow-up. A high score is equivalent to more symptoms. CRT = chemoradiotherapy; PO = 
postoperatively
  
 Figure 3. Mean dysphagia scores during treatment and follow-up. A high score is equivalent to more symptoms. CRT = chemoradiotherapy; PO = 
postoperatively
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operatively and the average role functioning score within one year after surgery. The 
average physical functioning score was still significantly and ≥ 0.5 SD decreased one 
year postoperatively compared to baseline.
The emotional functioning scores showed a different pattern over time. The mean 
score improved gradually and significantly during follow-up from three months after 
surgery. 
Most treatment related symptoms and local tumor symptoms recovered to baseline 
levels by nine months postoperatively, except for dyspnea (Figure 2,3). 
Over time, we observed no difference in global QoL between pathological responders 
(n=32) to CRT and pathological non-responders (n=20). However, global QoL was sig-
nificantly higher in responders than in non-responders six months postoperatively (11 
points, p=0.04). Over time, the pain score from the QLQ-C30 questionnaire was on aver-
age 8 points lower (i.e., less pain) in responders than in non-responders (p=0.04). This 
difference was larger three months postoperatively (17 points, p=0.01), and six months 
postoperatively (22 points, p=0.002).
diSCuSSion
We found significant and clinically relevant deterioration of most aspects of HRQoL dur-
ing concurrent neoadjuvant CRT with paclitaxel and carboplatin for esophageal cancer. 
Analyses demonstrated a decline in average scores for four functioning HRQoL scores. 
All symptom scores worsened during CRT. One year postoperatively all scores from 
both questionnaires were restored to baseline scores. The emotional functioning score 
Figure 4. Mean global quality of life scores during treatment and follow-up. A high score is equivalent to a better quality of life. CRT = 
chemoradiotherapy; PO = postoperatively
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showed a different pattern; it was worst at baseline, and showed a gradual increase over 
time during CRT and after surgery.  
Only two papers empirically addressed the impact of neoadjuvant CRT on HRQoL in 
patients with esophageal cancer undergoing an esophagectomy [8, 9]. Blazeby et al. [8] 
found that preoperative CRT for esophageal carcinoma had a temporary negative effect 
table 4. Mean Quality of Life scores ± SD during treatment and follow-up
Baseline
mean (SD)
PostCRT mean 
(SD)
3 months PO 
mean (SD) 
6 months PO 
mean (SD) 
9 months PO 
mean (SD) 
1 year PO 
mean (SD) 
QlQ-C30
Number of 
questionnaires
50 49 46 43 44 40
Global health score 78 (15) 61* (22) 70* (15) 75 (18) 75 (22) 80 (13)
functional scales
Physical functioning 95 (8) 73* (18) 75* (20) 83* (19) 84* (20) 88* (13)
Role functioning 91 (17) 54* (30) 60* (25) 74* (28) 76* (32) 84 (20)
Emotional functioning 74 (19) 74 (23) 82 (20) 85* (18) 84 (24) 88* (15)
Cognitive functioning 93 (13) 84* (19) 88 (17) 87 (19) 88 (19) 92 (14)
Social functioning 92 (16) 79* (23) 82 (24) 87 (18) 83 (28) 92 (13)
Symptom scales/items
Fatigue 14 (15) 52* (26) 36* (22) 28* (19) 25 (23) 19 (16)
Nausea/vomiting 7 (12) 26* (27) 21* (25) 13 (19) 12 (19) 9 (14)
Pain 11 (15) 34* (28) 17 (21) 11 (21) 15 (23) 11 (19)
Dyspnea 7 (15) 26* (23) 27* (26) 20* (24) 21* (25) 17 (24)
Insomnia 22 (27) 29 (26) 23 (31) 12 (23) 15 (23) 13 (21)
Appetite loss 6 (16) 45* (26) 25* (31) 15 (27) 13 (26) 10 (20)
Constipation 6 (16) 19* (25) 9 (18) 3 (10) 5 (12) 5 (14)
Diarrhea 3 (9) 16* (31) 22* (23) 19* (23) 11 (20) 12 (24)
Financial difficulties 2 (8) 5 (14) 8 (21) 3 (10) 8 (19) 8 (18)
oeS18
Number of 
questionnaires
49 48 46 41 44 39
Symptom scales/items
Dysphagia 23 (23) 40* (30) 20 (21) 12* (16) 14 (22) 9* (13)
Eating 24 (22) 45 (26) 32 (23) 21 (19) 23 (24) 17 (14)
Reflux 8 (18) 14 (19) 13 (17) 13 (17) 18* (20) 18* (22)
Pain 16 (18) 32* (25) 11 (13) 8* (12) 7* (10) 8* (13)
Trouble swallowing 
saliva
7 (15) 18 (29) 8 (17) 10 (19) 11 (28) 9 (18)
Choking 2 (8) 4 (13) 11 (17) 8 (16) 5 (14) 8 (16)
Dry mouth 9 (19) 26* (29) 18 (28) 7 (14) 15 (25) 9 (15)
Taste 5 (18) 35* (36) 10 (22) 8 (19) 4 (13) 4 (11)
Cough 9 (15) 31* (29) 29* (29) 17 (29) 18 (25) 12 (18)
Speech 2 (8) 10 (22) 9 (19) 2 (7) 6 (9) 5 (16)
CRT = chemoradiotherapy; PO = postoperatively; QLQ-C30 = Quality of life core questionnaire; OES-18 = esophageal site-specific
questionnaire.
Values expressed as mean ± SD.
* Change in score of ½ SD or greater and p < 0.05 compared with baseline   
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on most aspects of HRQoL, but that neoadjuvant CRT did not delay the postoperative 
recovery of HRQoL. They even stated that patients who had undergone neoadjuvant 
CRT reported earlier recovery of some aspects of HRQoL than patients undergoing sur-
gery alone (nausea, emesis, and dysphagia). Reynolds et al. [9] found that HRQoL was 
affected adversely by neoadjuvant CRT in the short term, despite a significant improve-
ment in dysphagia score. HRQoL three months after surgery was significantly lower 
compared to baseline both in patients treated with surgery alone, as in patients treated 
with multimodality treatment. However, there was no difference between these both 
groups. Global QoL scores had returned to baseline values by one year after surgery in 
the multimodal group. Patients in the multimodal group even had a significantly higher 
global QoL score than those who had surgery alone at this time point.
The pattern of decline of the various aspects of HRQoL during neoadjuvant CRT in pa-
tients with esophageal cancer in our study was comparable to the patterns found in the 
studies from Blazeby [8] and Reynolds [9]. The largest differences between post-CRT 
and baseline scores found in their studies were also found in our study (physical and 
role functioning, and fatigue). However, in our study more aspects of HRQoL declined 
during CRT, and the deterioration after CRT was for most aspects more pronounced 
than in the studies from Blazeby [8] and Reynolds [9]. In addition, global QoL decreased 
significantly by 17 points during the neoadjuvant treatment, whereas global QoL scores 
did not significantly change in the studies by Blazeby [8] and Reynolds [9]. Besides, the 
mean dysphagia score worsened significantly by 17 points during the CRT, whereas the 
mean dysphagia score improved in the study from Reynolds, and worsened at the end 
of the treatment after an initial improvement in the study from Blazeby [8].
These differences are intriguing, because compared to other studies with neoadjuvant 
CRT in esophageal cancer the incidence of grade 3 and 4 toxicity (according to the Na-
tional Cancer Institute – Common Toxicity Criteria (NCI-CTC)) in our study was low [10]. 
Apparently, in patients treated with neoadjuvant CRT, HRQoL is not only determined 
by the severity of toxicity according to the NCI-CTC.  This is especially reflected by the 
discrepancy between the measured rate of esophagitis grade 3 of 7% (according tot 
the NCI-CTC), and the significant increased mean dysphagia score after CRT (according 
to the OES18 questionnaire). The more pronounced deterioration of symptom scores 
in our study may be caused by the different CRT regimens used. In the study from Bla-
zeby [8] neoadjuvant CRT consisted of four cycles of cisplatin 60 mg/m2 and 12 weeks 
of continuous infusional 5-fluourouracil (5-FU) initially 300 mg/m2, reduced to 225 
mg/m2 during radiotherapy. After week 6 radiotherapy, 45 Gy in 5 weeks was given. 
Results of the objective toxicity of this regimen have not been reported so far. In the 
study from Reynolds [9], chemotherapy consisted of two courses of 5-FU (15 mg/kg) 
and cisplatin (75 mg/m2), and was repeated at week 6. Radiotherapy, 40 Gy in 3 weeks, 
started on the first day of the first course of chemotherapy. The objective incidence 
of grade 3 and 4 toxicity of this regimen was slightly higher than in our study [17]. An 
explanation for the deterioration of global QoL during CRT may be that global QoL is 
at least partly determined by the severity of symptoms. This is supported by the results 
from the univariate analyses in our study, which showed that the difference in physical 
functioning, role functioning, cognitive functioning and fatigue between post-CRT and 
baseline had a significant effect on global QoL just after CRT. Another explanation for 
the more pronounced deterioration of symptom scores and the deterioration of global 
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QoL during CRT may be the timing of assessment of HRQoL after CRT. In our study, the 
questionnaires were filled in one week after finishing CRT. At this time point patients 
usually experience most toxicity. In the study from Blazeby [8], QoL was assessed at two 
time-points: 5 and 12 weeks after starting the preoperative treatment. In the study from 
Reynolds [9], the questionnaires were filled in 3-4 weeks after finishing CRT (personal 
communication with Professor J. V. Reynolds, 2007), at which time toxicity may already 
have recovered.
Despite the negative impact of the CRT and esophagectomy, some aspects of HRQoL 
improved during the postoperative follow-up period compared to baseline. The mean 
score for emotional functioning had significantly improved one year postoperatively. 
This improvement in emotional well-being post-therapy compared to baseline (i.e., 
post-diagnosis but preceding treatment) has been described before in cancer patients 
[18]. It may be hypothesized that the diagnosis of cancer is the main stressor (not the 
treatment) and that treatment reduces distress. The scores for dysphagia and pain from 
the OES18 questionnaire were also significantly better than at baseline. This improve-
ment in symptoms can be ascribed to treatment success.
Most deteriorated aspects of treatment related symptoms had returned to baseline lev-
els by nine months postoperatively. However, the dyspnea score was still significantly 
increased by 10 points compared to baseline one year postoperatively. Although we 
found a small objective decline in pulmonary function tests (total lung capacity (TLC), 
vital capacity (VC), and forced expiratory volume in one second (FEV1)), this may not 
be the only explanation. Another explanation may be a decline in physical condition, 
resulting in dyspnea. However, the physical functioning scale and the fatigue score were 
restored to baseline level one year postoperatively.
One other aspect was also negatively affected. From nine months postoperatively, 
the mean score for reflux was significantly increased compared to baseline.  After 
esophagectomy the continuity of the upper digestive tract is restored by means of a 
gastric tube reconstruction. This reconstruction can lead to gastro-esophageal reflux in 
up to 20% of the patients [19].  It is unlikely that the preoperative CRT has had an effect 
on this; this deterioration in the reflux score was also described by Blazeby et al.[8], but 
surprisingly not by Reynolds et al [9]. 
No difference in global QoL between responders and non-responders could be found. 
However, over time the pain score was on average 8 points lower in responders com-
pared to non-responders. Because we could not find a difference in overall survival 
between responders and non-responders [10], a good explanation for this difference 
cannot be given. The difference in pain score between responders and non-responders 
was most distinct six months postoperatively. This might have led to the significantly 
higher global QoL found in responders six months postoperatively.
A drawback / limitation  of our study is the fact that the aspects of HRQoL of patients 
treated with neoadjuvant therapy and surgery are not compared with that of patients 
treated with surgery alone. Blazeby et al. [8] and Reynolds et al. [9] addressed this is-
sue, but  did so in a non-randomized assessment of patients treated with multimodality 
therapy or surgery alone, with the choice of treatment dependent on the doctor’s or 
patient’s preference. Prospective studies on the impact of an esophagectomy on HRQoL 
have shown that most aspect of HRQoL deteriorate in the early postoperative period, 
leading to reduced global QoL scores [20]. Nevertheless, these reduced scores gradually 
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recover within nine months after surgery.  There is, however, a difficulty with interpret-
ing the results from all these kind of studies. The reports on postoperative HRQoL only 
include data from patients who are still alive and sufficiently fit to fill in the question-
naires. This may lead to an overestimation of QoL, because Blazeby showed that in pa-
tients who died within 2 years of surgery QoL never recovered to baseline before death 
occurring from recurrent disease [3].
In conclusion, the current study shows that preoperative treatment with paclitaxel and 
carboplatin concurrent with radiotherapy for esophageal cancer has a profound, but 
temporary negative effect on most aspects of HRQoL. This effect is mostly restored one 
year after esophagectomy. Whether this neoadjuvant regimen leads to an impaired 
and/or delayed recovery of HRQoL after surgery needs to be examined in a randomized 
phase III trial with this CRT regimen followed by surgery versus surgery alone, which trial 
is now ongoing. However, in this study no indication for an impaired and/or delayed 
recovery was found. The time of assessment of HRQoL post-CRT (one week after finish-
ing CRT) may have influenced the results, because at this time point the toxicity of CRT 
usually is at maximum. Given the discrepancy found between the seriousness of toxicity 
assessed by the NCI-CTC and by the symptom scales and items of the QLQ-C30 and 
OES18 questionnaires, one can conclude that HRQoL assessment gives additional infor-
mation on toxicities of CRT regimens.  HRQoL considerations are especially important 
for patients and their treating physicians because the survival benefit of preoperative 
CRT is still not well established. Therefore, the findings of the study presented here can 
be used to inform patients about what to expect from this multimodality treatment for 
resectable esophageal cancer and hence contribute to the process of shared decision-
making on treatment choice.
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abStraCt
purpose. This study was performed in order to determine the residual tumor cells after 
preoperative chemoradiation and to correlate the effect of specific pathologic and clini-
cal findings to overall survival.
methods and materials. Esophageal biopsies and surgical specimens of 67 patients 
treated with neoadjuvant paclitaxel and carboplatin concurrent with radiotherapy were 
reviewed for: histological type, tumor grade, resection margins, extension of the tumor 
through the esophageal wall, nodal involvement, and tumor regression grade. From all 
patients survival was calculated.
results. After chemoradiotherapy tumors were more frequently graded as poorly dif-
ferentiated than before treatment. Complete tumor regression was found in 24% of the 
patients. Although not statistically significant, this resulted in a prolonged survival for 
these patients. Squamous cell carcinoma responded significantly higher to chemoradio-
therapy than adenocarcinoma. This was not associated with a survival benefit. Neoadju-
vant chemoradiotherapy led to a significant down-staging. Patients with pre-treatment 
nodal involvement had a significantly worse survival compared to patients with no pre-
treatment nodal involvement. This applied not for post-treatment nodal involvement.
Conclusions. Poorly differentiated esophageal tumors significantly more frequent 
reach complete tumor regression after neoadjuvant chemoradiotherapy. The presence 
of nodal involvement as assessed by endoscopic ultrasound is significantly associated 
with a worse survival.
introduCtion
Neoadjuvant chemoradiotherapy for patients with resectable esophageal cancer is 
increasingly used in an attempt to improve these patients. After chemoradiotherapy 
several histological changes in the resected specimen can be identified. These changes 
include cytological alterations such as cytoplasmic vacuolation and/or eosinophilia, 
nuclear pleomorphism, and necrosis, as well as stromal changes such as fibrosis (with 
or without inflammatory infiltrate), including giant cell granuloma formulation around 
ghost cells and mucin pools or keratin pearls at the site of the previous tumor [1-4]. On 
the basis of these changes, the grade of tumor regression can be defined. Regression of 
the primary tumor can range from the absence of regressive changes to a total response 
with no vital residual tumor cells. Several morphologic criteria have been defined for 
various types of cancer to objectively evaluate pathological response to neoadjuvant 
chemoradiation [1, 2, 5].  
The prognosis of resectable esophageal cancer is mainly determined by the achieve-
ment of a complete tumor resection (R0 resection), the depth of tumor infiltration, and 
the presence of lymph node metastasis [6-9]. Generally, the overall survival after neoad-
juvant chemoradiotherapy is better in patients with a complete pathological response 
compared to patients with residual tumor cells [6, 8, 10-12]. Schneider et al. and Brücher 
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et al. found that patients with only a few residual tumor cells within the resection speci-
men (<10%) had a significant better survival compared with patients with >10% re-
sidual tumor cells. 
In this article we review our experience with neoadjuvant carboplatin and paclitaxel concur-
rent with radiotherapy in patients with resectable esophageal cancer. We determined the 
residual tumor cells after preoperative treatment, and correlated the effect of specific patho-
logic and clinical findings to overall survival, in order to obtain prognostic information.
methodS and materialS
Acquisition of clinical data
We examined the esophageal biopsies and surgical specimens of all patients who were 
treated with neoadjuvant chemoradiation followed by surgery for esophageal cancer 
at the Erasmus Medical Centre between February 2001 and August 2006. Patients with 
T1N1 or T2-3N0-1 esophageal cancer were treated at our institution with five weekly 
courses of paclitaxel and carboplatin with concurrent radiotherapy followed by surgery 
in a phase II or phase III trial as described elsewhere [13].  
The clinical data collected included patient age, sex, and preoperative clinical stage 
(obtained from CT scan and EUS). 
Pathological analysis
All haematoxylin and eosin (H&E) slides from preoperative tumor biopsies and from the 
resection specimens were evaluated by a specialized pathologist (H.v.D.). The preopera-
tive tumor biopsies were viewed for histological tumor type, and grade. The resection 
specimen was evaluated using a standard protocol, providing information on margins, 
tumor type, tumor differentiation grade, extension of the tumor, and lymph nodes. If no 
macroscopically identifiable tumor was present, lesions such as an ulcer or an irregular 
area covered by mucosa were embedded in total together with surrounding areas in order 
to adequately judge the presence of residual tumor and therapy effects. The slides from 
the resection specimens were viewed for the presence of vital tumor cells near the oral, 
ab-oral and circumferential resection margins, tumor type, tumor differentiation grade, 
extension of the tumor in the esophageal wall, and number of involved lymph nodes. 
R0 was defined as histologically tumor-free resection margins with ≥ 1 mm distance be-
tween tumor and resection margins. The 6th edition of the International Union Against 
Cancer (UICC) was used for TNM-classification, tumor grade, and stage grouping [14]. 
Estimation of Treatment Effect
The grading of the therapy response was performed according to Junker et al.  as de-
scribed before [2, 13]. The degree of histomorphological regression in the esophageal 
wall, i.e. the effect of chemoradiation, was classified into four categories: tumor regres-
sion grade (TRG) I: more than 50% vital residual tumor cells; TRG II: 10-50% vital residual 
tumor; TRG III: less than 10% vital residual tumor cells; TRG IV: complete tumor regres-
sion, no evidence of vital tumor cells (Figure 1). Special attention was paid to therapy 
effects, such as mucin pools and squamous remnants in resection margins and lymph 
nodes (Figure 1).
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Statistical analysis
Patient characteristics are described using tables for categorical data, medians and 
ranges for continuous variables. Association between clinical and pathological param-
eters was evaluated using the chi-square test.
Overall survival time was calculated from the time of start of the chemoradiotherapy to 
the date of death or last follow-up. November 15th 2007 was the censoring date for sur-
vival. Survival curves were estimated using the Kaplan-Meier method, and the log-rank 
test was used to evaluate the statistical significance of differences. The SPSS statistical 
package (version 12.0; SPSS Inc., Chicago, IL) was used for all statistical analyses.
reSultS
Patient characteristics
The 67 patients who were assessed in the current study had a median age of 59 years 
and the majority was male. Baseline patient characteristics are summarized in Table 1.
table 1. Baseline Characteristics
Characteristic number (%)
Total number of patients 67
Sex
 Male 58 (87)
 Female 9 (13)
Age (years)
 Median 59
 Range 40-75
cT-stage (EUS)
 T2 9 (13)
 T3 49 (73)
 No pass 9 (13)
cN-stage (EUS)
 N0 29 (43)
 N1 38 (57)
Primary site
 Thoracic oesophagus 13 (19)
 Lower oesophagus 54 (81)
Histology
 Adenocarcinoma 46 (69)
 Squamous cell carcinoma 29 (28)
 Large cell carcinoma 2(3)
Grading
 Good 2 (3)
 Moderate 50 (75)
 Poor 13 (19)
 Undifferentiated 2 (3)
cT-stage: pre-treatment tumour stage; EUS: endoscopic ultrasound; cN-stage: post-treatment nodal stage
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Pathological analysis and association with pre-treatment and postoperative pathological factors
The morphological changes in the tumor and in non-neoplastic tissue: such as mucin 
pools, squamous remnants, and stromal changes are shown in Figure 1. In Table 2 path-
ological characteristics of the resection specimens are summarized. A complete micro-
scopic and macroscopic tumor resection was achieved in 66 of 67 patients (98.5%). In 
these 66 cases there were no mucin pools or areas containing keratin pearls or squamous 
remnants in the resection margins.
When there were still vital tumor cells left in the resection specimen, the tumor differ-
entiation grade was poorer compared to the tumor differentiation grade in the esopha-
geal biopsies before chemoradiotherapy: Seven patients had differentiation grade 3/4 
before chemoradiotherapy versus 27 patients after chemoradiation (p<0.001). TRG IV 
was achieved in 16 patients (24%), in 10 resection specimens (15%), little or no regres-
sive changes were seen (TRG I).  The response to chemoradiotherapy (as defined by TRG 
III and IV) was significantly higher in patients with squamous cell carcinoma (SCC) than 
in patients with adenocarcinoma (AC) (68% versus 54%, p=0.001). Poorly differentiated 
tumors (grade 3/4, esophageal biopsies) achieved significantly more tumor regression 
grade IV than good or moderately differentiated tumors (53% vs. 15%, p<0.01).
Fifty-seven patients (85%) had tumor infiltration into the adventitia (T3) at baseline 
assessed by EUS, versus 25 patients (37%) after therapy as assessed by pathological 
analysis of the resection specimen, indicating significant downstaging by chemoradio-
Figure 1. H&E images illustrating the effects of chemoradiation on esophageal adeno- and squamous cell carcinomas. a] TRG I, adenocarcinoma 
with no or little therapy effect. b] TRG II, residual squamous cell carcinoma and therapy effects (squamous remnant, arrow). C] TRG III, few residual 
tumor cells (arrows) surrounded by fibrosis of the adventitia and the muscular layer. d] TRG IV, an ulcer is seen directly above the muscular layer 
showing fibrosis, but no vital tumor cells. e, f] TRG IV, showing mucin lakes and squamous remnants (arrows), respectively, but no vital tumor cells. 
g, h] lymph nodes displaying mucin and keratin squames, respectively, in the subcapsular sinus (arrow), no tumor cells. i,J] well differentiated 
adenocarcinoma in the preoperative biopsy (i), and moderately (to poorly) differentiated adenocarcinoma in the resection specimen (J), illustrating 
downgrading after chemoradiation. K, l] likewise, moderately differentiated (keratinizing, arrow) squamous cell carcinoma in the preoperative 
biopsy (K), and poorly differentiated squamous cell carcinoma after chemoradiation (l). A 4x objective was used in A-F, 10x in G-H, and 20x in I-L.
2
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therapy (p<0.0001). Likewise, 38 patients (57%) had pre-treatment nodal involvement, 
as assessed by EUS, versus 21 patients (31%) post-therapy, as assessed by pathological 
examination of the resected specimen (p=0.006). In 11 of the 29 resected specimens 
with no pre-treatment nodal involvement (38%) regression effects were identified in the 
lymph nodes, suggesting downstaging from clinical stage N1 to pathological stage N0. 
The tumor regression grade of the primary tumor was significantly related to the risk of 
residual tumor cells in the esophageal wall: pT3 was found in 80% for TRG I, 65% for TRG 
II, and 25% for TRG III (p=0.01). This also applied for the resected lymph nodes: positive 
lymph nodes were found in 70% for TRG I, 50% for TRG II, 20% for TRG III, and 14% for 
TRG IV (p=0.008).
Pathological analysis and association with overall and disease free survival
After a median follow-up of 35 months (range 2-75), 20 patients relapsed (1 patient had 
a local/regional relapse, 9 patients developed distant metastases, and 10 patient devel-
oped both). The presence of pre-treatment nodal involvement was significantly associ-
ated with the development of distant metastases (14% vs. 42%, p=0.02). The median 
overall survival as calculated by the Kaplan Meier method has not yet been reached 
(Figure 2A). There was a trend towards a better overall survival in patients with a com-
plete regression, i.e. TRG IV (p=0.09). The median overall survival for patients with TRG I-
III was 57 months; the median survival for patients with TRG IV has not yet been reached 
(Figure 2B). Survival was significantly better in patients who had no nodal involvement 
table 2. Histopathological Characteristics of oesophagectomy specimens
Characteristic number (%)
Completeness of resection
 R0 66 (99)
 R1 1 (1)
Regressiongrade
 I 10 (15)
 II 17 (25)
 III 24 (36)
 IV 16 (24)
ypT category
 T0 16 (24)
 T 13 (19)
 T2 13 (19)
 T3 25 (37)
ypN category
 N0 45 (67)
 N1 21 (31)
 Unknown 1 (1)
Grading
 No tumour 16 (24)
 Good 1 (1)
 Moderate 23 (34)
 Poor 27 (40)
ypT: posttherapy pathological tumour stage; ypN-stage: posttherapy pathological nodal stage;
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before the start of treatment (median survival has not yet been reached) compared to 
patients who had nodal involvement as assessed by EUS (median survival 39 months, 
p=0.03) (Figure 3). No difference in overall survival could be found between patients 
with pathological nodal involvement compared to patients with no pathological nodal 
Figure 2. Overall Survival (A) and overall survival of patients with TRG IV compared to patients with residual disease (TRG I-III) (B)
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involvement, including 11 patients (16.7%) with therapy effects within the lymph nodes. 
There was no survival difference between patients with AC or SCC.
Figure 3. Overall survival of patients with (A) pre-treatment nodal involvement compared to patients with no nodal involvement, (B) post-treatment 
nodal involvement compared to patients with no nodal involvement
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diSCuSSion
In this study we described the histopathological changes seen after neoadjuvant chemo-
radiotherapy with paclitaxel and carboplatin in 67 cases of esophageal carcinoma. When 
vital tumor cells were left in the esophageal wall after chemoradiotherapy, the tumor 
was graded more frequently as poorly differentiated than before treatment. There are 
3 explanations for the worsened differentiation grade in the resected specimens. First, 
poorly differentiated tumor cells may be more resistant to the cytotoxic insult caused 
by neoadjuvant therapy. However, TRG IV was more frequently found in pretreatment 
poorly differentiated tumors, so this does not seem to be a likely explanation. Second, it 
might be caused by “sampling error” of the pretreatment esophageal biopsies, because 
the tumor differentiation grade of the resected specimen is determined by the worst 
differentiation found. Lastly, cytotoxic injury of chemoradiotherapy may induce dedif-
ferentiation of tumor cells. Changes in differentiation of tumor cells after chemoradio-
therapy have been described before [10, 15, 16]
We found complete tumor regression (TRG IV) in 24% of the patients, which corresponds 
with the rates found in other studies with neoadjuvant chemoradiotherapy in patients 
with esophageal cancer [17-20]. It has been well known that patients who achieve a 
pathological response after neoadjuvant chemoradiotherapy have a significantly pro-
longed survival compared to patients with residual vital tumor cells in the resection 
specimen [10, 12].  A survival difference between patients who had TRG IV and those 
who did not have TRG IV was observed, although it did not yet reach statistical signifi-
cance. Because of the 98% complete resection rate in our study we could not assess the 
prognostic significance of a complete resection. It is however well known from other 
studies that a complete resection is associated with a better survival [9, 11]. 
In our study, the response to chemoradiotherapy was significantly higher in patients 
with SCC than in patients with AC. However, this did not translate in a better survival 
for these patients. This difference in response between SCC and AC has been described 
before [21]. Rohatgi et al. found that among the patients with a complete response in 
clinical stage II, there was a significantly greater proportion of SCC patients (77% versus 
63%; p <0.001) than AC patients. However, among the patients with a total response in 
clinical stage III, a significantly greater proportion were AC patients than SCC patients 
(38% versus 23%; p <0.001) [22]. The difference in response to chemoradiotherapy 
between these two histological subtypes might be caused by the different etiological 
background, molecular profiles and patient genetics of these two subtypes. 
The proportion of patients with tumor infiltration into the adventitia (T3) was signifi-
cantly higher before treatment than after treatment. This applied for nodal involvement 
as well. This difference in pre-treatment and postoperative stage is most probably due 
to the chemoradiation, since we found an inverse correlation between the TRG and 
pathological tumor infiltration into the esophageal wall and the pathological nodal 
involvement. 
In our study, patients with pre-treatment nodal involvement had a significantly worse 
survival compared to patients with no pre-treatment nodal involvement. This survival 
difference between patients with and without nodal involvement was not found after 
chemoradiotherapy. The presence of pre-treatment nodal involvement is predictive for 
the development of locoregional relapse and the development of distant metastases, so 
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it is possible although CRT had a beneficial effect on local control the outcome of these 
patients with pre-treatment nodal involvement is still poor because nodal metastases 
are indicative for occult distant metastases. This phenomenon was also found by Jiao et 
al. [23]. They found that the presence of pre-treatment lymph node metastases as deter-
mined by thoracoscopy was significantly correlated with a worse survival. Our finding 
that the overall survival did not differ between patients with or without nodal involve-
ment assessed after neoadjuvant chemoradiotherapy followed by surgery is in contrast 
with the results found by others [4, 6, 24]. Rice et al. found that survival was significantly 
worse in patients with clinical and/or pathological nodal involvement [24]. Bollschweiler 
et al. even reported that the prognosis of patients with esophageal cancer treated with 
neoadjuvant chemoradiotherapy followed by esophagectomy was determined by the 
number of involved lymph nodes [6]. Patients with more than five involved regional 
lymph nodes had a significantly worse prognosis than patients with one to five affected 
lymph nodes, and those with no involved lymph nodes had the best prognosis. 
In conclusion, in this study we found that poorly differentiated tumors significantly 
more frequent reached TRG IV in patients with resectable esophageal cancer after treat-
ment with neoadjuvant chemoradiotherapy followed by surgery. Besides, we observed 
in this study that the presence of nodal metastasis as assessed by EUS was significantly 
associated with a worse survival, in contrary with the presence of nodal metastasis after 
CRT as assessed by pathological analysis. 
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abStraCt
Background The purpose of the current phase II study was to assess the safety and ef-
ficacy of oxaliplatin and capecitabine in patients with metastatic or local-regional unre-
sectable esophageal cancer.
methods. Eligible patients received oxaliplatin 130 mg/m2 intravenously on day 1 
and capecitabine 1,000 mg/m2 orally twice daily on days 1 to 14 in a 21-day treatment 
cycle. 
results. Fifty-one patients were enrolled. Grade 3/4 hematological toxicities were: 
grade 3 neutropenia (2%) and grade 3 anemia (2%). Grade 4 non-hematological toxicity 
(lethargy) occurred in one patient (2%). Grade 3 non-hematological toxicity was seen in 
14 (27%) patients. In 22% of the patients toxicity was the reason for stopping the treat-
ment. The overall response rate was 39%. The median overall survival was 8 months; 
the 1 year survival rate was 26%. In the quality of life (QoL) analysis the emotional well-
being improved during treatment, the physical functioning scores declined. The fatigue 
score on the symptom scales increased. Overall, the global QoL score did not change 
during treatment.
Conclusions. The activity of oxaliplatin and capecitabine is comparable to other che-
motherapy regimens in metastatic or local-regional unresectable esophageal cancer. 
The frequency of grade 3/4 toxicity was low and the quality of life was maintained dur-
ing the treatment. Because this treatment is probably less toxic than cisplatin-based 
therapy, with preservation of quality of life during treatment, and because it can be 
given on an outpatient basis, this regimen is a viable treatment option in patients with 
advanced esophageal cancer.
introduCtion
Patients with esophageal cancer generally have a poor prognosis, because the major-
ity of them already have locally unresectable or metastatic disease at presentation. 
Furthermore, even after surgery with curative intent , local recurrences and/or distant 
metastases are detected in approximately two-third of the patients within five years 
of follow-up [1]. Many patients with esophageal cancer require palliative therapy to 
treat symptoms, such as dysphagia. Placement of a self-expanding metal stent, external 
beam radiotherapy, intraluminal radiotherapy (brachytherapy), and laser therapy are 
commonly used palliative modalities to treat dysphagia [2].
Palliative chemotherapy may result in local and distant tumor control and symp-
tom control. The effect of chemotherapy on survival is unclear, mainly due to a lack 
of randomized trials. The most frequently used chemotherapy regimen for patients 
with metastatic disease is a combination of 5-fluorouracil and cisplatin, with response 
rates ranging from 15%-45% [3]. However, treatment with 5-fluorouracil and cisplatin 
can induce severe toxicity [4]. Besides, most patients have to be hospitalized for this 
treatment. In two trials a significant positive effect of chemotherapy on quality of life 
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and/or overall survival was demonstrated [5, 6]. However, in both trials patients with 
esophageal and gastric cancer (predominantly adenocarcinomas) were treated. There 
are no studies comparing the effect of chemotherapy and other palliative treatments on 
symptom control (e.g. dysphagia).
Capecitabine is a novel oral fluoropyrimidine carbamate, which is converted into 
5-fluorouracil preferentially in tumors. Clinical studies with capecitabine have been 
predominantly performed in colorectal and breast cancer. In a study performed by Hoff 
et al. in patients with advanced colorectal cancer [7], treatment with capecitabine was 
at least as effective as treatment with 5-fluorouracil plus leucovorin, but leaded to less 
hospitalizations for adverse reactions.
Oxaliplatin is a third-generation platinum compound. It forms inter- and intrastrand 
cross-links with DNA. These cross-links inhibit DNA replication and transcription. It has 
demonstrated synergy with 5-fluorouracil in advanced colorectal cancer [8]. 
The combination of oxaliplatin and capecitabine has been tested in several phase II 
studies in patients with metastatic colorectal cancer [9, 10]. Grade 3/4 diarrhea was seen 
in 33-50% of the patients treated with capecitabine 1,250 mg/m2 twice daily and oxalip-
latin 130 mg/m2 in the study performed by Borner et al [9]. Cassidy et al reported grade 
3/4 diarrhea in 16% of the patients treated with oxaliplatin 130 mg/m2 and capecitabine 
1,000 mg/m2 twice daily. The response rate was comparable, 49% and 55%, respectively. 
Therefore, a capecitabine dose of 1,000 mg/m2 twice daily on days 1 to 14 in combi-
nation with oxaliplatin 130 mg/m2 on day 1 in a 21-day treatment cycle is the recom-
mended dose.
Based on these favorable results of oxaliplatin combined with capecitabine in other 
gastrointestinal malignancies, we conducted the present phase II study to evaluate the 
safety and efficacy of the combination of oxaliplatin and capecitabine in patients with 
metastatic or local-regional unresectable carcinoma of the esophagus, esophagogastric 
junction and cardia. In addition, to evaluate the effects of this schedule on the patients’ 
well-being we performed a quality of life analysis in these patients during the treat-
ment.
methodS
Eligibility criteria
Eligible patients had histologically proven metastatic or local-regional unresectable 
carcinoma of the esophagus or gastric junction, and at least one unidimensionally mea-
surable lesion ≥ 20 mm using conventional computed tomography (CT) or magnetic 
resonance imaging (MRI) scan or ≥ 10 mm using spiral CT scan had to be present. Pa-
tients were required to be aged at least 18 years, to have an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of ≤ 2 and a life expectancy of ≥ 3 months. Other 
criteria included adequate hematological, renal, and hepatic functions as defined by: 
granulocyte count of at least 1,500/mm3 and platelet count 100,000/mm3; serum crea-
tinine ≤ 1.25 x the upper normal limit (ULN); aspartate aminotransferase (AST) and ala-
nine aminotransferase (ALT) ≤ 3 x the ULN (≤ 5 x the ULN in case of liver metastases) and 
bilirubin ≤ 1.25 x ULN. Previous neoadjuvant treatment for non-metastatic disease was 
allowed if completed at least six months prior to the initiation of study treatment. Prior 
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treatment with oxaliplatin or capecitabine was not allowed. No history of malignancy, 
apart from non-melanomatous skin cancer, curatively treated carcinoma in situ of the 
cervix or a “cured” malignancy more than five years prior to enrollment was allowed. Pa-
tients with evidence of central nervous system metastases, a lack of physical integrity of 
the upper gastrointestinal tract, a malabsorption syndrome, or an inability to take oral 
medication were excluded. Patients were not eligible if they had a preexisting motor 
or sensory neurotoxicity > grade 1 according to the National Cancer Institute Common 
Toxicity Criteria (NCI-CTC version 3). The Ethics Committee at Erasmus University Medi-
cal Center approved the study, and written informed consent was obtained. 
Treatment
Treatment consisted of oxaliplatin 130 mg/m2 intravenously on day one and capecitabi-
ne 1000 mg/m2 orally twice daily on days 1-14 (28 doses), repeated every three weeks. 
Oxaliplatin diluted in 250 mL glucose 5% was administered as a continuous infusion 
over two hours. Capecitabine had to be ingested with water every 12 hours, approxi-
mately 30 minutes after a meal, starting at the evening of day one. Dose modifications 
were made for toxicity, using the NCI-CTC (version 3). The absolute neutrophil count 
and the platelet count had to be recovered to the required pretreatment values before 
start of the next treatment cycle. Non-hematological toxicity had to be ≤ grade 1 before 
start of every treatment cycle. If these conditions were not met, dosing was delayed 
for a maximum of two weeks. If hematological or non-hematological toxicity was not 
recovered to grade 1 or less after two weeks, patients were taken off-study. 
Persistent (≥ 14 days) paresthesia or temporary (7-14 days) painful paresthesia or func-
tional impairment prompted a 25% dose reduction of oxaliplatin. In case of persistent 
(≥ 14 days) painful paresthesia or functional impairment, oxaliplatin had to be omitted 
until recovery and had to be restarted at 50% of the dose. Patients went off-study if 
these toxicities recurred despite the dose reductions. 
Capecitabine was reduced with 25% in case of grade 2 hand-foot-syndrome. In case of 
grade 2-4 diarrhea, capecitabine intake had to be interrupted immediately. Standard 
treatment for diarrhea was prescribed (i.e. loperamide).  The omitted doses were not 
permitted to be administered after resuming treatment, and the total length of capecit-
abine treatment period was not allowed to exceed 14 days. If patients experienced 
severe capecitabine-related toxicity (> grade 2) despite two dose reductions, necessitat-
ing discontinuation of treatment with capecitabine, patients were taken off-study.
Patients who showed no disease progression and/or prohibitive toxicity continued treat-
ment for six courses, with a maximum of eight courses in case of ongoing response.
Pretreatment and follow-up evaluation
Pretreatment evaluation included a detailed history taking, a physical examination and 
routine blood examinations. All patients underwent a baseline computed tomography 
(CT) of the chest and the upper abdomen. After discontinuation of treatment follow-up 
visits were done every three months to document late toxic effects, disease progression 
and survival. 
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Evaluation of response and toxicity
Patients were evaluable for response after two courses of chemotherapy. Evaluation of 
response was done every other course of chemotherapy. However, if tumor progres-
sion was found at any time after randomization, it was recorded as progressive disease. 
Tumor response was assessed according to the Response Evaluation Criteria In Solid 
Tumors (RECIST) [11]. The duration of response was measured from the time of com-
plete or partial response until the first date of recurrent or progressive disease. Stable 
disease was measured from the start of treatment until the criteria for progression were 
met. Progression free and overall survival was documented from the time of patient 
randomization until tumor progression or death.
Quality of life assessment
Quality of life was measured using the EORTC QLQ-C30 (version 3.0) and QLQ-OES18 
[12, 13]. Questionnaires were filled in before therapy, after every other cycle, and after 
completion of chemotherapy. Patients with missing forms were excluded from the anal-
ysis of the absent assessment point. Scores were calculated according to the guidelines, 
yielding a range of 0-100. A higher score for a functional scale represents a higher level 
of functioning. A higher score for a symptom scale/item represents a higher level of 
symptomatology/problems [14]. Because high drop-out rates result in more favorable 
scores among the remaining patients, comparisons were only made between baseline 
and after the second course, and between baseline and after stopping chemotherapy.
Statistical analysis
An optimal two-stage design for phase II trials as described by Simon was used [15]. 
In the first stage, a total of 13 patients were included and at least four responses were 
required to continue to the second stage. In the second stage, 30 additional patients 
were included to a total sample size of at least 43. Thirteen responses were needed to 
conclude with a 95% confidence that the response rate was greater than 40%. Statistical 
differences in quality of life at different time points were determined using the t-test. All 
tests were two sided at the .05 level of significance. The SPSS statistical package (version 
12.0; SPSS Inc., Chicago, IL) was used for all statistical analyses.
reSultS
Patient Characteristics
From April 2003 to October 2005 fifty-one patients were included in this study. The 
baseline characteristics are summarized in Table 1. The majority of the patients was 
male (86%) and most of them had adenocarcinoma (88%). 
Toxicity of and adherence to chemotherapy
The median number of treatment cycles was four (range 1-8). Apart from progression 
of disease or end of protocol, reasons for stopping chemotherapy were toxicity (22%), 
patient’s request (4%), and clinical deterioration (2%). The dose of capecitabine was 
reduced in 5 patients (10%), due to diarrhea (n=3) or hand foot syndrome (n=2). In 4 pa-
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tients the administration of capecitabine was prematurely interrupted due to diarrhea. 
The dose of oxaliplatin was reduced in three patients, due to painful paresthesia. 
Hematological toxicity is summarized in Table 2. Apart from one case each of grade 
3 neutropenia and grade 3 anemia, no grade 3 or 4 hematological toxicities were ob-
served. In the latter patient analysis showed an undetectable haptoglobin, and an in-
creased LDH and bilirubin, indicating hemolysis, which has been described in relation 
to oxaliplatin administration [16]. 
Non-hematological toxicity is summarized in Table 2. Eighteen patients were hospital-
ized during treatment. In eight patients this was directly related to the treatment (dehy-
dration caused by anorexia, nausea, vomiting, and/or diarrhea (n=6), grade 4 lethargy 
(n=1), observation for one night in hospital after laryngopharyngeal dysesthesia (n=1)). 
In two patients the hospitalization was possibly related to the treatment (venous throm-
boembolism). The eight other hospitalizations were due to disease related problems, 
table 1.  Baseline characteristics
Characteristic number (%)
Gender
 Male 44 (86)
 Female 7 (14)
Age (years)
 Median 60
 Range 31-76
WHO
 0 20 (39)
 1 30 (59)
 Missing 1(2)
Weight loss (%)*
 < 5% 17 (33)
 5-10% 17 (33)
 > 10% 13 (26)
 Missing 4 (8)
Histology
 Adenocarcinoma 45 (88)
 Squamous cell carcinoma 4 (8)
 Undifferentiated carcinoma 2 (4)
Prior chemoradiotherapy/chemotherapy
 Yes 6 (12)
 No 45 (88)
Prior surgery
 Transhiatal esophagectomy 17 (33)
 Laparotomy, without resection 4 (8)
Sites of metastases
 Lymph nodes 37
 Liver 23
 Lung 16
 Locoregional recurrence 8
 Other 8
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such as dysphagia requiring esophageal stenting, jaundice, ileus, pericarditis, fever and 
tumor related bleeding. 
Response
Forty-nine patients were evaluable for response. No complete responses were seen. 
Nineteen patients (39%) achieved a partial response, 21 patients (43%) had stable dis-
ease, and nine patients (18%) had disease progression. The median duration of response 
was 5.3 months (range 2-18).
Survival
All 51 patients were evaluable for survival. At the date of evaluation (April 15th, 2006) 
43 patients have died. The median survival time for all patients was 8 months (95% CI 
6-9 months, range 2 to 27 months). The one year overall survival was 26%; the two-year 
overall survival was 7%.
Quality of life (QoL)
Hundred-forty-one of 165 expected questionnaires were completed (85%). Four patients 
were excluded because QoL data were not obtained before the start of treatment. The 
scores of the responders were not different from the scores of the non-responders.
From 41 patients we obtained the QLQ-C30 questionnaires at baseline and after the 
second course, from 39 patients the OES18 questionnaires at these time points. Al-
though the physical functioning score declined significantly from 85 to 78 (p=0.04), 
the emotional functioning score improved significantly from 61 to 73 (p=0.003). The 
other functional scores did not change. The sleeping score of the EORTC QLQ-C30 de-
creased significantly from 34 to 16 (p=0.006), indicating improvement of sleeping. The 
pain score from the EORTC QLQ-OES18 decreased significantly from 16 to 9 (p=0.045), 
indicating less pain. The score for dry mouth increased significantly from 5 to 14 (0.005). 
No significant changes were seen in the other symptom scores.  
table 2. Hematological and non-hematological toxicities
Grade
0 1 2 3 4
No. (%) No. (%) No. (%) No. (%) No. (%)
Anaemia 7 (14) 36 (70) 7 (14) 1 (2) -
Leucopenia 43 (84) 6 (12) 2 (4) 12 (22.6) 1 (1.9)
Neutropenia 45 (88) - 5 (10) 1 (2) -
Thrombocytopenia 31 (61) 15 (29) 5 (10) - -
Nausea 9 (18) 29 (57) 10 (19) 3 (6) -
Vomitus 21 (41) 20 (39) 6 (12) 4 (8) -
Anorexia 36 (71) 10 (19) 4 (8) 1 (2) -
Diarrhea 23 (45) 23 (45) 4 (8) 1 (2) -
Lethargy 6 (12) 30 (59) 12 (23) 2 (4) 1 (2)
Hand foot syndrome 42 (82) 3 (6) 4 (8) 2 (4) -
Polyneuropathie (sensory) 4 (8) 34 (67) 11 (21) 2 (4) -
Polyneuropathie (motor) 47 (92) 1 (2) 1 (2) 2 (4) -
Hyperbilirybinemia 39 (76) 8 (16) 3 (6) 1 (2) -
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From 33 patients we obtained the QLQ-C30 questionnaires at baseline and after stop-
ping chemotherapy, from 31 patients the OES18 questionnaires at these time points. 
Scores on the physical functioning scale declined from 88 to 78 (p=0.02), but scores on 
the emotional functioning scale improved from 60 to 71 (p= 0.02).  From the symptom 
scales of the EORTC QLQ-C30, the sleeping score decreased significantly from 34 to 17 
(p=0.03), indicating less symptoms. However, the fatigue score increased significantly 
from 30 to 43 (p=0.003), indicating more fatigue. From the symptom scales of the EORTC 
QLQ-OES18, the pain score decreased significantly form 15 to 7 (p=0.02), indicating less 
pain. The dry mouth score increased significantly from 5 to 20 (p=0.01), indicating wors-
ening of complaints from a dry mouth. No significant changes were seen in the other 
symptom scores.
The global QoL score was 63 at baseline and 62 after the second course and after stop-
ping chemotherapy.
diSCuSSion
Our study showed no major hematological toxicity, except for grade 3 anemia in one 
patient and grade 3 neutropenia in another patient. Grade 3 or 4 non-hematological 
toxicity was uncommon as well. However, in 22% of the patients toxicity was the reason 
for stopping the chemotherapy (grade 2 toxicity in 7/11 patients and grade 3 or 4 in 
4/11 patients). The most (in more than 85% of the patients) reported toxicities were 
constitutional, namely lethargy and polyneuropathy, but these were of mild to moder-
ate intensity. Other frequently (in more than 50% of the patients) reported toxicities 
were gastrointestinal (nausea, vomiting and diarrhea), which were also generally of mild 
to moderate intensity. These toxicities were comparable to that found in the study of 
Cassidy et al. [10] in patients with metastatic colorectal cancer, as were the reasons for 
withdrawal from therapy. In one other phase II study the combination of oxaliplatin 
and capecitabine was tested as first-line treatment in patients with metastatic adeno-
carcinoma of the esophagus, gastro esophageal junction and gastric cardia [17]. Grade 
3 and 4 gastrointestinal toxicity and lethargy were more common in this study, neuro-
logical and hematological toxicities were not mentioned. The toxicity prompted a dose-
reduction of capecitabine to 825 mg/m2, because of four treatment-related deaths. An 
explanation for this difference in toxicity can not be found, because the baseline char-
acteristics of the patients enrolled in both studies seem to be comparable. However, 
this regional differences in mainly gastrointestinal tolerability for fluoropyrimidines 
between the United States and the rest of the world have been described before [18]. In 
another phase II study performed in 54 patients with advanced gastric cancer [19], the 
toxicity of this regimen was comparable to the toxicity in our trial. 
Our study showed an median overall survival of 8 months, which is in line with the 
results from other studies performed at our institution in patients with metastatic or 
local-regional unresectable esophageal cancer [20]. However, the 1 year survival in our 
study was slightly worse compared to that observed in previous studies at our institu-
tion (26% vs. 33%). This might be explained by the fact that in our study more patients 
with poor prognostic factors such as liver metastases were included (45% versus 23%). 
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Improving or maintaining quality of life and achieving symptom relief are important 
goals in the management of patients with metastatic esophageal cancer. In this study 
patients reported an improvement in emotional well-being after two courses of che-
motherapy as well as after stopping the chemotherapy. This is intriguing, because the 
physical functioning scores declined significantly over the same period. The reason for 
this decline in the physical functioning scores is most probably caused by the increase 
of fatigue, which was stated more frequently after stopping chemotherapy (median af-
ter 4 courses). This increase in fatigue score may be due to the treatment, but in about 
half of the patients, the treatment was stopped due to disease progression, which can 
also lead to a higher level of fatigue. The improvement of emotional well-being during 
chemotherapy can not be easily comprehended. Possibly, a better way of coping with 
the diagnosis of incurable cancer throughout time leads to this improvement. Secondly, 
the very act of undergoing treatment, may also lead to an improvement of emotional 
well-being. It has been described that the QoL improves during chemotherapy, despite 
considerable toxicity [21]. Besides, it is well known that patients are willing to undergo 
treatments that have small benefits with major toxicity [22].
Overall, the global QoL score at baseline did not change over time. In the study of Ross 
et al [5] the global QoL scores were maintained with epirubicin/ cisplatin/ 5-fluorouracil, 
but declined with mitomycin/cisplatin/5-fluorouracil. In that study the QoL scores de-
clined over time, but the follow-up of questionnaires was longer than in our study (up 
to one year after treatment). In the study of Webb et al. [6] the global QoL scores were 
maintained and showed no difference between arms at 12 weeks (P = .71), but at 24 
weeks the difference became more pronounced (P = .04), with the epirubicin/cisplatin/5-
fluorouracil scores maintained and the 5-fluorouracil/adriamycin/ methotrexate scores 
lower. 
In conclusion, our study shows that the activity of the combination of oxaliplatin 130 
mg/m2 intravenously on day 1 and capecitabine 1000 mg/m2 orally twice daily on days 
1-14 in a 21-day cycle is comparable to other chemotherapy regimens in metastatic or 
local-regional unresectable esophageal cancer. The frequency of grade 3/4 toxicity was 
low and the quality of life was maintained during the treatment. Because this treatment 
is probably less toxic than cisplatin-based therapy, with preservation of quality of life 
during treatment, and because it can be given on an outpatient basis, this regimen is a 
viable treatment option in patients with advanced esophageal cancer.
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Summary
Oesophageal cancer is a highly lethal disease, as reflected by an overall survival rate of 
10-20%. This is due to the fact that most patients who present with complaints, such as 
dysphagia, have either locally advanced or metastatic disease. Even after surgery with 
curative intent, overall survival remains poor. In approximately two-third of the patients 
local recurrences and/or distant metastases are detected within five years of follow-up. 
Explanations for this high number of local recurrences and metastases are that tumour 
spread to lymph nodes occurs rather early in tumorigenesis due to the presence of a 
submucosal lymph node plexus [1] and the presence of lymph node metastases is very 
strong adverse prognostic factor. Furthermore, approximately 30% of the oesophageal 
resections are microscopically irradical [2-4]. 
Chemotherapy is nowadays frequently used in the treatment of oesophageal cancer. 
The goal of preoperative and postoperative chemotherapy is a reduction of local recur-
rences and lymphatic and/or distant spread, with improvement in survival. Besides, pre-
operative chemotherapy can lead to possible tumour shrinkage allowing an increased 
radical resectability rate. Chemotherapy in combination with radiotherapy can be used 
as a part of a multimodality treatment or as definitive treatment. Theoretically, chemo-
therapy and radiotherapy can interact in several ways. Both treatment modalities may 
be active against different tumour cell populations; the chemotherapy may be effec-
tive against micrometastases, while radiation is active locoregionally. Moreover, che-
motherapy may synchronise cells in a vulnerable phase for radiotherapy. Preoperative 
chemoradiotherapy can induce considerable tumour shrinkage and thereby increase 
the number of radical resections. Many studies have reported that after chemoradio-
therapy in 10–28% of the patients no tumour cells are found in the resection specimen 
(pathological complete response (pCR)) [5-9]. Several studies have shown that a pCR is 
associated with a better prognosis [10, 11].
Chemotherapy can also be used in the treatment of patients with metastatic disease. 
Palliative chemotherapy may result in local and distant tumour and symptom control 
and this may result in a survival benefit as well.
Chapter 2 is a review article that focussed on the use of chemotherapy alone or as part of 
combined modality treatment in patients with oesophageal cancer. The evidence avail-
able from the literature was used to discuss whether chemotherapy can be considered 
as an integral part of standard treatment or should still be considered experimental with 
its impact on survival and quality of life unproven or unknown. The conclusion that can 
be derived is that it is feasible to administer chemoradiotherapy preoperatively and that 
chemotherapy and radiotherapy can be combined as definitive treatment. Although 
there are indications that preoperative chemotherapy or preoperative chemoradio-
therapy may have an impact on survival, the precise extent, if any, is still unknown. It is 
also unknown whether the benefit outweighs the increased treatment-related toxicity. 
The uncertain impact of preoperative chemotherapy or chemoradiotherapy is caused 
by the fact that most performed phase III studies are underpowered or flawed by a poor 
design.
The evidence that chemotherapy may be beneficial for patients with metastatic dis-
ease can be derived from only two trials in which both patients with oesophageal and 
gastric cancer were treated. The most important conclusion that can be derived from 
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this overview of the literature concerning the treatment with chemotherapy or chemo-
radiotherapy is that most of these studies are feasibility studies, phase 2 studies and 
underpowered phase 3 studies. 
In Chapter 3 a phase 2 study is reported in which the safety and efficacy of an outpatient 
preoperative chemoradiotherapy regimen, consisting of five weekly courses of carbo-
platin and paclitaxel and concurrent 23 daily radiotherapy fractions for 54 patients with 
resectabel oesophageal cancer. Fifty-three patients (98%) completed the preoperative 
treatment. The treatment was well tolerated by the patients. Grade 3-4 toxicities were: 
neutropaenia 15%, thrombocytopaenia 2%, and oesophagitis 7.5%. The pathological 
complete response rate was 25%. All patients had an R0-resection (microscopically radi-
cal). At the time of analysis the median overall survival had not yet been reached. The 
estimated 3-year survival rate was 56%. A major advantage of this treatment regimen is 
that it can be given on an outpatient basis. A multicentre randomised phase 3 trial with 
this regimen followed by surgery versus surgery alone in now ongoing in the Nether-
lands. 
Chapter 4 describes the results of a quality of life analysis in 54 patients with oesopha-
geal cancer treated with curative intent by neoadjuvant chemoradiotherapy followed 
by oesophagectomy. Because of the trade-off between the potentially negative quality 
of life effects and the uncertain favourable survival effect of neoadjuvant chemoradio-
therapy in these patients, the health-related quality of life was assessed for up to one 
year postoperatively in patients treated with preoperative chemoradiotherapy with a 
non-cisplatin based outpatient regimen followed by surgery. Patients undergoing this 
treatment completed standardized health related quality of life questionnaires. Differ-
ences in generic and condition-specific health related quality of life scores over time 
were analysed, using a linear mixed effects model. The generic quality of life was assessed 
with the quality of life core questionnaire (QLQ-C30) from the European Organisation for 
Research and Treatment of Cancer (EORTC). The condition-specific health related quality 
of life was assessed with a site-specific questionnaire for oesophageal cancer (OES18) 
from the EORTC. Mean scores of most health related quality of life scales deteriorated 
significantly during neoadjuvant chemoradiotherapy. The largest deterioration was 
observed for physical and role functioning scales. Postoperatively, most mean health 
related quality of life scores improved until recovery to baseline level. The emotional 
functioning score showed a different pattern; it was worst at baseline, and increased over 
time during chemoradiotherapy and postoperatively. The dysphagia and pain scores 
worsened considerably during chemoradiotherapy, restored to baseline three months 
postoperatively, and were even significantly better one year postoperatively. The time 
of assessment of the health related quality of life after chemoradiotherapy (one week 
after finishing the treatment) might have influenced the results, because at this time 
point the toxicity of chemoradiotherapy is at maximum. Given the discrepancy found 
between the seriousness of toxicity assessed by the National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) and by the symptom scales and items of the QLQ-C30 and 
OES18 questionnaires, one can conclude that health related quality of life assessment 
gives additional information on toxicities of chemoradiotherapy regimens. 
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After chemoradiotherapy several histological changes in the resected specimen can be 
identified. On the basis of the histological changes, the grade of tumour regression can 
be defined. Regression of the primary tumour can range from the absence of regressive 
changes to a total response with no vital residual tumour cells (complete pathological 
response). In Chapter 5 an overview is given from the Rotterdam experience with neo-
adjuvant carboplatin and paclitaxel concurrent with radiotherapy in 67 patients with 
resectable oesophageal cancer. The residual tumour cells after preoperative treatment 
were determined, and the effect of specific pathologic and clinical findings to overall 
survival was correlated. In 60% of the patients a good response to chemoradiotherapy 
was seen (<10% vital tumour cells in the resected specimen). A complete pathological 
response was found in 24% of the patients. The proportion of patients with tumour 
infiltration into the adventitia (T3) was significantly higher before treatment than after 
treatment. This applied for nodal involvement as well. When vital tumour cells were left 
in the oesophageal wall after chemoradiotherapy, the tumour was graded more fre-
quently as poorly differentiated than before treatment. This might be explained by the 
fact that poorly differentiated tumour cells may be more resistant to the cytotoxic insult 
caused by neoadjuvant therapy. On the other hand, a complete pathological response 
was more frequently found in pre-treatment poorly differentiated tumours. Achieving a 
complete pathological response did result in an obvious trend toward a survival benefit. 
The presence of nodal metastasis as assessed by EUS was significantly associated with a 
worse survival, in contrast to the presence of nodal metastasis after CRT as assessed by 
pathological analysis.
In Chapter 6 the results of a phase 2 study with palliative chemotherapy are reported. 
In this study we assessed the safety and efficacy of the combination of oxaliplatin and 
capecitabine in a 21-day treatment cycle as first-line therapy in 51 patients with ad-
vanced cancer of the oesophagus, oesophagogastric junction or cardia. In addition, the 
effects of this schedule on the patients’ well being were evaluated by a quality of life 
analysis on these patients during the treatment. Grade 3 neutropaenia was seen in one 
patient and anaemia in another. No grade 4 haematological toxicities were observed. 
Grade 4 non-haematological toxicity (lethargy) occurred in one patient (2%). Grade 3 
non-haematological toxicity was seen in 14 (27%) patients (nausea, vomiting, anorexia, 
diarrhoea, polyneuropathy, lethargy, hand-foot syndrome, and hyperbilirubinaemia). 
Despite the fact that grade 3 or 4 toxicity was uncommon, toxicity was the reason for 
stopping the treatment in 22% of the patients. The overall response rate was 39%. The 
median overall survival was 8 months. In the quality of life analysis, the emotional well 
being improved during treatment, but the physical functioning scores declined. The 
fatigue score on the symptom scales increased. Overall, the global quality of life score 
did not change during treatment. Because this treatment can be given on an outpatient 
basis, and is probably less toxic than cisplatin-based therapy and preserves quality of 
life during treatment, it might be a viable treatment option in patients with advanced 
oesophageal cancer. 
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future perSpeCtiveS 
Theoretically, there are several ways to improve the high mortality rate of oesophageal 
cancer. First, reducing the incidence of oesophageal cancer could lower the total number 
of patients diagnosed yearly with this devastating disease. Secondly, by improving the 
selection of patients who might benefit from surgical treatment, the survival resected 
patients might increase. Finally, the development of better diagnostic and treatment 
approaches can ameliorate the prognosis of patients with oesophageal cancer. 
Reducing the incidence of owsophageal cancer
Until the 1970s the incidence of squamous cell carcinoma exceeded the incidence of 
adenocarcinoma of the oesophagus in the Western world. Tobacco smoking and alcohol 
abuse are the main risk factors for the development of squamous cell cancer of the 
oesophagus. Although there are no known intervention trials studying the impact of 
the cessation of smoking on the incidence of this type of oesophageal cancer, cessa-
tion of smoking is believed to be an important prevention measure. Unfortunately, of 
the smokers who try to quit only a minority succeeds [12]. Maybe, the introduction of 
new pharmacotherapies to treat nicotine dependency can have a beneficial effect [13]. 
In Linxian China, the oesophageal cancer mortality rate is extremely high. There is a 
suspicion that the population’s chronic deficiencies of micronutrients are etiologically 
involved. Therefore, randomized, placebo-controlled nutrition intervention trials were 
performed to test the effect of vitamin and mineral supplements for 6 years in lower-
ing the incidence rate of cancer. Results from the General Population Trial showed that 
those who received the β-carotene-vitamin E-selenium combination had a 13% reduc-
tion in cancer mortality, and a 4% decrease in deaths from oesophageal cancer, after a 
relatively short period of follow-up [14]. Results from the Dysplasia Trial showed that 
supplementation reduced the likelihood of having oesophageal dysplasia after both 
30 and 72 months of intervention [14]. With dysplasia being a premalignant lesion, the 
effect of the nutrition intervention on mortality might therefore increase in the future.
Over the last decades there has been a substantial increase in the incidence of adenocar-
cinomas of the lower third of the oesophagus in Western countries. Adenocarcinomas 
of the oesophagus are associated with obesity [15], gastro-oesophageal reflux disease 
[16], and Barrett’s metaplasia [17-19]. Oesophageal cancer arising from a Barrett’s oe-
sophagus is thought to arise within the ‘Barrett’s metaplasia-low grade dysplasia-high 
grade dysplasia-carcinoma sequence’. While only 0.2-2% of the patients with Barrett’s 
oesophagus will eventually develop oesophageal cancer [20, 21], there is still an in-
creased risk. Besides, the detection of these premalignant lesions by random biopsies 
is troubled by sampling error and by the intra- and interobserver variation of histologi-
cal assessment. New developments in both endoscopy technique and tissue sampling 
might improve early diagnosis of high grade dysplasia and cancer [22]. In addition, the 
presence of genetic alterations in metaplastic and dysplastic Barrett’s epithelium might 
be used in the future surveillance of patients with Barrett’s oesophagus, since these 
molecular markers could identify a subset of patients with an increased risk of malig-
nant degeneration. For example, patients with an increase of tetraploid or aneuploid 
cell populations in Barrett’s epithelium, were found to be at a higher risk for developing 
invasive carcinoma during follow-up (RR 7.5) [23].
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For those patients diagnosed with Barrett’s metaplasia, prevention of progression to oe-
sophageal cancer is an important goal. Whether the interventions that inhibit the devel-
opment of inflammatory mediators and reduce acid reflux and bile exposure may offer 
a cost-effective and widely applicable treatment option is currently being investigated 
in the AspECT trial. In this phase III trial patients with a Barrett’s oesophagus circumfer-
ence of 3 cm or greater are randomised to receive continuous low- or high-dose proton 
pump inhibitor therapy with or without aspirin. 
Development of novel diagnostic strategies
Even after surgery with curative intent, the overall survival after an oesophagectomy 
remains poor. The identification of those patients who may or may not benefit from 
surgery is therefore of utmost importance. Positron emission tomography (PET) has 
become a major diagnostic tool for the detection of mediastinal lymph nodes and 
extrathoracic metastases in non-small cell lung cancer [24]. However, the diagnostic 
yield of a PET-scan to improve the selection of patients with oesophageal cancer for 
potentially curative surgery is limited after “state-of-the art” staging [25, 26]. On the 
other hand, a PET-scan might be a useful diagnostic tool that allows for accurate predic-
tion of tumour response early during chemoradiotherapy. Data suggest that metabolic 
changes in tumour tissue as measured by FDG-PET predict response better than EUS 
or a CT-scan [27]. Whether a PET-scan predicts early in the treatment the non-response 
to neoadjuvant chemoradiotherapy in patients with potentially curable oesophageal 
cancer is currently being investigated in the NEOPEC-trial in the neoadjuvant arm of 
a randomized multicentre Dutch trial comparing neoadjuvant chemoradiotherapy fol-
lowed by surgery versus surgery alone (see below).  
The stage of the disease as expressed in the TNM staging system [28], is one of the 
most important prognostic factors for patients with oesophageal cancer. Lagarde et al. 
showed that besides TNM staging, the number of positive lymph nodes or the positive/
negative lymph node ratio, extracapsular lymph node involvement, radicality of oe-
sophagectomy, and tumour size are important prognostic factors as well [29]. In some 
other tumour types the presence of prognostic features may influence subsequent treat-
ment decisions, such as the administration of adjuvant chemotherapy in case of nodal 
involvement in breast and colorectal cancer, or the start of palliative chemotherapy in 
case of a high PSA doubling time in prostate cancer. For oesophageal cancer up till now, 
no such treatment decisions are linked to the presence of prognostic factors. However, 
molecular pathology has revealed a vast number of genes and molecules, which are 
related to tumour invasion and metastasis, and in that way also to prognosis. In pa-
tients with breast cancer, overexpression of the HER2/neu protein is associated with an 
aggressive behaviour of the tumour [30]. Trastuzumab, a humanized monoclonal anti-
body against the extracellular domain of HER2, has been shown to benefit patients with 
HER2-positive breast cancer [31, 32]. Several prognostic factors of genes and molecules 
in adenocarcinoma of the oesophagus have been established, like HER2/neu, TGF-β, 
p53, COX2, E-cadherin, β-catenin, UPA, MMP-1, DNA aneuploidy, and >50% promotor 
hypermethylation. The targeting of these pathways may enhance the therapeutic op-
tions for patients with this type of cancer [33].
Recently, it has become possible to detect, enumerate, and characterise circulating tu-
mour cells (CTCs) reliably [34]. Potential applications of this are: establishing prognosis, 
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serving as a marker to assess treatment-induced anti-tumour activity, detecting recur-
rent disease, elucidating prognostic and predictive factors, and exploring biological 
processes (dissemination, drug resistance, and therapy-induced cell death). Likely, the 
detection, enumeration and characterization of CTCs will form a valuable attribution to 
medical oncology in terms of research and patient management purposes in the near 
future.
Development of novel therapeutic approaches
Oesophageal surgery is associated with considerable peri-operative morbidity and 
mortality, especially in low-volume hospitals [35]. The concentration of oesophageal 
surgery in high volume hospitals may have a positive effect on the morbidity and mor-
tality. Another important reason to centralize the treatment of patients with oesopha-
geal cancer is the presence of multidisciplinary consultations teams in most of these 
high volume hospitals.
A conclusion concerning neoadjuvant chemoradiotherapy of the review article in this 
thesis was that the role of preoperative chemoradiation is still unclear. Recently, a meta-
analysis showed a significant 2-year survival benefit for preoperative chemoradiotherapy 
and, to a lesser extent, for preoperative chemotherapy in patients with carcinoma of the 
oesophagus [36]. However, because this meta-analysis is based on mostly inadequately 
performed and underpowered phase 3 studies, the strength of the conclusions of such 
meta-analyses is questionable. Yet, the concept of neoadjuvant chemoradiotherapy re-
mains very appealing. Therefore, and because of the favourable results from our phase 
2 study with neoadjuvant carboplatin and paclitaxel with concurrent radiotherapy fol-
lowed by oesophagectomy, we are currently involved in a randomised phase 3 trial with 
this preoperative chemoradiotherapy regimen followed by surgery versus surgery alone 
(CROSS-trial). This study has, up to now, included more than 300 patients.
Many questions remain concerning the optimal radiation dose and schedule and che-
motherapy schedule. By the use of newer chemotherapeutic agents, such as taxanes 
and irinotecan, weekly or continuous administration of chemotherapy together with 
concurrent radiotherapy, hyperfractionated radiotherapy schedules, an improvement 
in treatment outcome might be achieved. Targeted therapy with a cyclooxygenase -2 
inhibitor, vascular endothelial growth factor inhibitors, epidermal growth factor recep-
tor blockers or mammalian target of rapamycin inhibitors are attractive means for com-
bining with radiotherapy or chemotherapy alone, or with chemoradiotherapy [37].
As stated, oesophageal surgery is associated with considerable peri-operative morbid-
ity and mortality. Apart from the severe physical impact, an oesophageal resection also 
has a major psychological and social effect [38-41]. An alternative, organ preserving, 
treatment regimen consisting of continuing chemoradiotherapy in patients responding 
to preoperative chemoradiation, thereby avoiding unnecessary additional surgery is 
an attractive treatment option. This strategy seems to be a reasonable treatment op-
tion with a comparable survival rate to surgery according to two studies [42, 43], al-
beit that the locoregional recurrence rate was higher in patients treated with definitive 
chemoradiation. However, appropriate selection criteria to identify patients who will 
respond to chemoradiotherapy would allow us to maximize the therapeutic benefit and 
to minimize toxicity. In order to prevent unnecessary toxicity, it would even be better to 
be able to predict response to chemoradiotherapy before start of the treatment. Sev-
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eral molecular markers have been tested for their potential to predict therapy response 
[44]. The authors found an association between the response of patients with Barrett’s 
adenocarcinoma to neoadjuvant chemotherapy with 5-fluorouracil and cisplatin and 
the expression levels of methylenetetrahydrofolate reductase (MTHFR), caldesmon (ac-
tinomyosin regulatory protein), and multidrug resistance protein 1 (MRP1), in part with 
a sensitivity of >90%. Further investigation is needed to develop diagnostic tools that 
may predict response to preoperative chemoradiotherapy by analyzing routine biop-
sies from tumour tissue.
The effect of oesophageal surgery with or without preoperative therapy on the qual-
ity of life of patients with oesophageal cancer is frequently not very well highlighted. 
Because health related quality of life assessments give additional information on tox-
icities of chemoradiotherapy regimens, and in order to investigate the possible effect 
of neoadjuvant chemoradiotherapy on an impaired and/or delayed recovery of health 
related quality of life after surgery, a quality of life analysis is performed with the above 
mentioned phase 3 study as well. Results from that study can be used to inform patients 
about what to expect from this multimodality treatment for resectable oesophageal 
cancer and hence contribute to the process of shared decision making about treatment 
choice.
For the many patients who present with metastatic disease or who relapse after surgery 
or definitive chemoradiotherapy no curative options are available. For these patients 
palliation of dysphagia and of symptoms such as pain and fatigue are important goals. 
Especially in this patient group improving or maintaining quality of life is extremely 
important. However, current standards for analyzing quality of life and symptom con-
trol in randomized controlled trials are poor. Definition of a palliative endpoint, with 
an a priori hypothesis, is essential; defining the proportion of patients with palliative 
response is preferred. A checklist could raise standards of reporting in future random-
ized controlled trials [45].
Placement of a self-expanding metal stent, external beam radiotherapy, intraluminal 
radiotherapy (brachytherapy), and laser therapy are commonly used palliative mo-
dalities to treat dysphagia [46]. Few studies have been performed to compare these 
treatment options. There are no studies comparing the effect of chemotherapy and 
other palliative treatments on symptom control (e.g. dysphagia). In one study the use 
of single-dose brachytherapy was compared with metal stent placement for the pallia-
tion of dysphagia in patients with oesophageal cancer [47]. Despite slow improvement, 
single-dose brachytherapy gave better long-term relief of dysphagia than metal stent 
placement. Since brachytherapy was also associated with fewer complications than 
stent placement and, moreover, since the effects of single dose brachytherapy on health 
related quality of life compared favourably to those of stent placement for the palliation 
of oesophageal cancer [48], it is recommended as the primary treatment for palliation 
of dysphagia from oesophageal cancer.
The results from the phase II trial studying the effect of the treatment with oxaliplatin 
and capecitabine of patients with metastatic or locally advanced oesophageal cancer 
in this thesis showed that palliative chemotherapy can maintain quality of life during 
treatment and might even improve symptoms (pain). The effect of chemotherapy on 
survival is unclear, mainly due to a lack of randomised trials. The conclusions from the 
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Cochrane Review concerning the use of chemotherapy for metastatic carcinoma of the 
oesophagus and gastro-oesophageal junction are that there is a need for well designed, 
adequately powered, phase III trials comparing chemotherapy versus best supportive 
care for patients with metastatic oesophageal cancer [49]. Chemotherapy agents with 
promising response rates and tolerable toxicity are cisplatin, 5-fluorouracil (5-FU), pacli-
taxel and anthracyclins. Future trials comparing palliative treatment modalities should 
assess quality of life with validated quality of life measures as well.
The increasing knowledge of the molecular biology of cancer and the development of 
new diagnostic tools and targeted agents offer new challenges and opportunities for 
the treatment of patients with oesophageal cancer and the development of more tailor 
made treatment strategies with the best benefit for our patients.
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Samenvatting
Slokdarmkanker is een zeer dodelijke ziekte, gezien de algemene overleving van 10-20%. 
Dit is het gevolg van het feit dat de meeste patiënten die zich presenteren met klachten 
zoals dysfagie al een vergevorderd of uitgezaaid stadium van de ziekte hebben. Ook na 
een oesofagusresectie met curatieve intentie, treedt er bij ongeveer éénderde van de 
patiënten binnen vijf jaar een ziekterecidief op in de vorm van een lokaal recidief en/of 
metastasen. Een verklaring voor dit grote aantal recidieven is het feit dat de tumor al in 
een vroeg stadium uitzaait naar de lymfklieren ten gevolge van de aanwezigheid van 
een submucosale lymfklierplexus en het feit dat de aanwezigheid van lymfkliermetas-
tasen een slechte prognostische factor is. Daarnaast is een oesofagusresectie tot in 30% 
van de gevallen niet radicaal.  
Chemotherapie wordt tegenwoordig frequent gebruikt in de behandeling van slok-
darmkanker. Het kan voor of na een oesofagusresectie gegeven worden met als doel 
een ziekterecidief ten gevolge van occulte lymfklier- of afstandsmetastasen te elimi-
neren om zo de overleving te verbeteren. Preoperatieve chemotherapie kan daarnaast 
de tumor doen krimpen, waardoor de kans op een radicale resectie vergroot wordt. 
Chemotherapie in combinatie met radiotherapie kan gebruikt worden als onderdeel 
van ‘multimodality’ behandeling of als definitieve behandeling. Er is een interactie van 
chemotherapie en radiotherapie op verschillende niveaus. Beide hebben antikanker ac-
tiviteit; chemotherapie kan effectief zijn tegen micrometastasen, terwijl radiotherapie 
locoregionaal werkt. Chemotherapie is bovendien in staat om cellen tijdens de celdeling 
in een bepaalde fase te houden, waarin de cellen beter gevoelig zijn voor radiotherapie. 
Het doel van preoperatieve chemoradiotherapie is afname van de tumorgrootte om 
zo de kans op een radicale resectie te vergroten. Veel studies hebben gerapporteerd 
dat na chemoradiotherapie bij 10-28% van de patiënten geen tumorcellen meer in het 
resectiepreparaat kunnen worden teruggevonden (complete pathologische respons 
(pCR)). Verscheidene studies hebben aangetoond dat zo’n pCR is geassocieerd met een 
betere prognose.
Chemotherapie kan ook gebruikt worden in de behandeling van patiënten met geme-
tastaseerde ziekte. Het doel van deze behandeling is controle van de locale tumor en van 
de afstandsmetastasen, zodat er symptoomvermindering optreedt. Een bijkomend voor-
deel van deze behandeling zou een toename van de levensverwachting kunnen zijn.
In hoofdstuk 2 werd een overzicht gegeven van het gebruik van chemotherapie alleen 
of als onderdeel van een gecombineerde behandeling (met radiotherapie en/of opera-
tie) bij patiënten met slokdarmkanker. Beschikbaar bewijs uit de literatuur werd gebruikt 
om te bediscussiëren of chemotherapie beschouwd kan worden als integraal onderdeel 
van de behandeling van patiënten met slokdarmkanker of dat het effect op overleving 
en kwaliteit van leven nog niet duidelijk is. De conclusie van het overzichtsartikel was 
dat de combinatie van chemotherapie met bestraling zonder veel problemen gegeven 
kan worden voor een slokdarmoperatie of goed gebruikt kan worden als definitieve 
behandeling voor slokdarmkanker. Hoewel er aanwijzingen zijn dat preoperatieve che-
motherapie of chemoradiotherapie enig effect kan hebben op de overleving, is de 
grootte van dit effect, als het er al is, nog niet duidelijk. Tevens is het nog niet duidelijk 
of de eventuele voordelige effecten op de overleving opwegen tegen de nadelige ef-
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fecten van deze behandeling. Het onzekere effect van preoperatieve chemotherapie of 
chemoradiotherapie wordt veroorzaakt door het feit dat de meeste fase 3 onderzoeken 
op dit gebied niet van voldoende grootte zijn of gekenmerkt worden door een slechte 
opzet. Het bewijs dat chemotherapie nuttig kan zijn bij patiënten met gemetastaseerd 
slokdarmkanker kan uit slechts twee studies geconcludeerd worden. Een beperking van 
deze twee studies is het feit dat zowel patiënten met slokdarmkanker als patiënten met 
maagkanker werden behandeld.
De belangrijkste conclusie die uit dit overzicht van de literatuur kan worden getrokken 
is dat met betrekking tot de rol van chemotherapie in de behandeling van patiënten 
met slokdarmkanker er voornamelijk fase 2 studies en fase 3 studies van onvoldoende 
grootte zijn gepubliceerd.
In hoofdstuk 3 werd een fase 2 studie besproken, waarin het effect en de bijwerkingen 
van een poliklinisch preoperatief chemoradiotherapie schema werd beschreven bij 54 
patiënten met een resectabel oesofaguscarcinoom. De behandeling bestond uit vijf 
wekelijkse toedieningen van paclitaxel en carboplatin gelijktijdig met 23 bestralingen 
op werkdagen. De behandeling werd voltooid door 98% van de patiënten en werd goed 
verdragen. De belangrijkste hematologische toxiciteit bestond uit een graad 3 neu-
tropenie bij 15% van de patiënten. De belangrijkste niet-hematologische toxiciteit was 
een graad 3 oesofagitis bij 7,5% van de patiënten. Bij 13 van de 52 (25%) patiënten die 
geopereerd werden, kon in het resectiepreparaat geen tumorcellen meer worden terug-
gevonden. Bij alle patiënten kon een microscopisch radicale operatie plaatsvinden. Ten 
tijde van het analyseren van de overlevingsdata was de mediane algemene overleving 
nog niet bereikt. De geschatte 3-jaars overleving was 56%. Het grote voordeel van dit 
schema is, is dat het poliklinisch kan worden toegediend. Een gerandomiseerde fase 3 
studie waarin deze preoperatieve behandeling gevolgd door operatie wordt vergeleken 
met operatie alleen bij patiënten met een resectabel oesofaguscarcinoom wordt nu in 
meerdere ziekenhuizen in Nederland uitgevoerd. 
hoofdstuk 4 beschrijft de resultaten van een kwaliteit van leven analyse gedurende 
preoperatieve chemoradiotherapie en na operatie bij 54 patiënten met een resectabel 
oesofaguscarcinoom. Gezien de afwegingen tussen de mogelijke negatieve effecten op 
de kwaliteit van leven en de onzekere positieve effecten op overleving van preopera-
tieve chemoradiotherapie gevolgd door een oesofagusresectie, werd in dit onderzoek 
de kwaliteit van leven beoordeeld tot één jaar na de operatie bij patiënten met een 
resectabel oesofaguscarcinoom. Op gezette tijden werden gestandaardiseerde vragen-
lijsten afgenomen. Het verschil in algemene kwaliteit van leven scores en de ziekte spe-
cifieke kwaliteit van leven scores over de tijd werd geanalyseerd. Voor de beoordeling 
van de algemene kwaliteit van leven werd de hoofdvragenlijst voor kwaliteit van leven 
(QLQ-C30) van de Europese Organisatie voor Onderzoek en Behandeling van Kanker 
(EORTC) gebruikt. Voor de ziekte specifieke kwaliteit van leven werd de ziektespecifieke 
vragenlijst (OES-18) van de EORTC gebruikt. De gemiddelde kwaliteit van leven scores 
daalden significant gedurende de preoperatieve chemoradiotherapie. De grootste da-
ling werd gezien voor fysiek en rol functioneren. Na de oesofagusresectie verbeterden 
de gemiddelde scores weer tot uitgangsniveau. Het emotioneel functioneren was slecht 
bij aanvang van de behandeling, maar verbeterde over de tijd significant. De scores 
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voor dysfagie en voor pijn verslechterden aanzienlijk tijdens de chemoradiotherapie, 
maar deze waren drie maanden na de operatie weer op uitgangsniveau en één jaar 
postoperatief zelfs beter dan bij aanvang van de behandeling. Het tijdstip waarop het 
effect van de chemoradiotherapie op de kwaliteit van leven werd beoordeeld (één week 
na staken van de chemoradiotherapie) kan een effect gehad hebben op de uitkomst 
van de analyse, aangezien op dat moment de toxiciteit van de behandeling het grootst 
is. Gezien het feit dat er een forse discrepantie bestond tussen gemeten toxiciteit met 
behulp van de National Cancer Institute Common Toxicity Criteria (NCI-CTC) en de 
symptomen gemeten met behulp van de kwaliteit van leven vragenlijsten (QLQ-C30 en 
OES-18), moet geconcludeerd worden dat kwaliteit van leven analyses extra informatie 
geven over de bijwerkingen van chemoradiotherapie schema’s. 
Na preoperatieve chemoradiotherapie kunnen in het uitgenomen slokdarmpreparaat 
diverse histologische veranderingen worden gezien; soms worden er zelfs helemaal 
geen tumorcellen meer in het resectiepreparaat teruggevonden (complete pathologi-
sche respons). Daarnaast is het mogelijk de mate van respons op chemoradiotherapie 
te kwantificeren. In hoofdstuk 5 wordt een overzicht gegeven van deze histologische 
veranderingen na preoperatieve chemoradiotherapie met paclitaxel en carboplatin ge-
combineerd met radiotherapie bij 67 patiënten met een resectabel oesofaguscarcinoom. 
Tevens werden deze histologische veranderingen samen met klinische karakteristieken 
gecorreleerd met overlevingsdata. Bij 60% van de patiënten trad een goede respons op 
na chemoradiotherapie (<10% tumorcellen over in het uitgenomen slokdarmpreparaat). 
Bij 24% was sprake van een complete pathologische respons. Ook bleek uit de resectie-
preparaten dat de uitbreiding van de tumor in de slokdarmwand significant minder was 
dan voor de behandeling en dat er bij minder patiënten lymfkliermetastasen konden 
worden gevonden. De tumor in het resectiepreparaat werd vaker als slecht gedifferen-
tieerd geclassificeerd dan voor start van de behandeling. Dit lijkt niet het gevolg te zijn 
van het ‘uitselecteren’ van slecht gedifferentieerde tumoren, aangezien tumoren die 
preoperatief als slecht gedifferentieerd waren beoordeeld, significant vaker een com-
plete pathologische respons lieten zien. Er bleek een duidelijke trend te bestaan tot een 
betere overleving voor patiënten die een complete pathologische respons hadden. De 
aanwezigheid van lymfkliermetastasen bij onderzoek met endo-echografie was signi-
ficant geassocieerd met een slechter overleving, in tegenstelling tot de aanwezigheid 
van lymfkliermetastasen in het resectiepreparaat na chemoradiotherapie.
In hoofdstuk 6 werden de resultaten van een fase 2 studie beschreven, waarin de vei-
ligheid en werking van de combinatie van oxaliplatin en capecitabine in een 3-wekelijks 
schema is beoordeeld als eerstelijns behandeling van 51 patiënten met een gemetasta-
seerd of lokaal vergevorderd oesofaguscarcinoom, junction tumor of cardiacarcinoom. 
Tevens werden de effecten van dit schema op het welbevinden van de patiënten getest 
met behulp van een kwaliteit van leven analyse gedurende de behandeling. De belang-
rijkste hematologische toxiciteit bestond uit een graad 3 anemie bij 2% en een graad 
3 neutropenie bij 2% van de patiënten. De belangrijkste niet-hematologische toxiciteit 
bestond uit een graad 4 lethargie en verscheidene graad 3 bijwerkingen (misselijkheid, 
braken, anorexie, diarree, polyneuropathie, lethargie, handvoetsyndroom en een hy-
perbilirubinemie) bij 27% van de patiënten. Ondanks deze relatief lage frequentie van 
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graad 3 en 4 toxiciteit, werd de behandeling bij 22% van de patiënten gestaakt omwille 
van voor de patiënt onacceptabele bijwerkingen. Het responspercentage was 39%. De 
mediane overleving was 8 maanden. De kwaliteit van leven analyse liet een achteruit-
gang van het fysiek functioneren zien, evenals een verslechtering van de vermoeid-
heidsscores. Het emotionele functioneren verbeterde gedurende de behandeling. De 
algemene kwaliteit van leven score veranderde niet gedurende de behandeling. Omdat 
deze behandeling poliklinisch kan worden gegeven en mogelijk minder bijwerkingen 
heeft dan cisplatin bevattende chemotherapieschema’s én aangezien de kwaliteit van 
leven gewaarborgd blijft gedurende de behandeling, kan dit schema als een bruikbare 
behandelingsoptie worden beschouwd voor patiënten met een gemetastaseerd of lo-
kaal vergevorderd oesofaguscarcinoom. 
toeKomStige ontwiKKelingen
Theoretisch zijn er verschillende manieren om de hoge mortaliteit van slokdarmkanker 
te verbeteren. Ten eerste kan een reductie van de incidentie van slokdarmkanker het 
aantal patiënten dat jaarlijks met deze verwoestende ziekte gediagnosticeerd wordt 
verlagen. Ten tweede kan de overleving geopereerde patiënten vergroot worden door 
een betere selectie van patiënten die baat hebben bij een chirurgische behandeling. Als 
laatste kan de prognose van patiënten met slokdarmkanker verbeterd worden door de 
ontwikkeling van betere diagnostische mogelijkheden en behandelingen. 
Vermindering incidentie slokdarmkanker
Tot de jaren zeventig was in de westerse wereld de incidentie van het plaveiselcel car-
cinoom van de slokdarm groter dan die van het adenocarcinoom. Roken en alcoholge-
bruik zijn de belangrijkste risicofactoren voor de ontwikkeling van het plaveiselcel carci-
noom van de slokdarm. Hoewel er geen bekende studies bestaan die het effect van het 
stoppen met roken op de incidentie van dit type slokdarmkanker hebben onderzocht, 
wordt aangenomen dat het stoppen met roken een belangrijk preventief effect heeft. 
Helaas slaagt slechts een minderheid van de rokers er in te stoppen. Misschien dat de 
introductie van nieuwe medicamenten om nicotine verslaving te bestrijden een positief 
effect heeft. In Linxian in China is de mortaliteit ten gevolge van slokdarmkanker zeer 
hoog. Vermoedelijk heeft dit te maken met de chronische deficiëntie van micronutriën-
ten onder de bevolking. Om die reden zijn gerandomiseerde, placebogecontroleerde 
voeding-interventie studies verricht om het effect van vitamine en mineralen supple-
menten gedurende 6 jaar op vermindering van de incidentie van slokdarmkanker te 
beoordelen. De resultaten van de ‘General Population Trial’ toonden dat die patiënten 
die de combinatie van β-caroteen-vitamine E-selenium kregen een 13% reductie had-
den in kanker mortaliteit, en een 4% daling in het aantal overledenen ten gevolge van 
slokdarmkanker. De resultaten van de ‘Dysplasia Trial’ toonden dat de supplementen de 
kans op het krijgen van dysplasie in de slokdarm na zowel 30 als 72 maanden vermin-
derden. Aangezien dysplasie een voorstadium is voor slokdarmkanker kan het effect 
van voeding-interventie op sterfte in de toekomst dus nog wel groter worden.
In de laatste decennia heeft er in westerse landen een sterke toename plaatsgevon-
den in de incidentie van adenocarcinomen van het laatste éénderde gedeelte van de 
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slokdarm. Adenocarcinomen van de slokdarm zijn gerelateerd aan overgewicht, gastro-
oesofageale reflux ziekte en Barrett’s metaplasie. Adenocarcinomen van de slokdarm 
die ontstaan uit een Barrett’s slokdarm, ontwikkelen zich waarschijnlijk via de ‘Barrett’s 
metaplasie-laaggradige dysplasie-hooggradige dysplasie-carcinoma’ volgorde. Hoewel 
slechts 0.2-2% van de patiënten met een Barrett’s slokdarm slokdarmkanker krijgt, is 
dit toch een verhoogd risico. Daarom lijkt screening en surveillance endoscopie met 
weefsel biopten bij patiënten met Barrett’s metaplasie een aantrekkelijke strategie 
om de incidentie van slokdarmkanker te verminderen. Echter, de huidige screening 
en surveillance richtlijnen voor Barrett’s slokdarm en de daaraan verwante neoplasie 
worden niet ondersteund door sterk bewijs. Eén van de redenen hiervoor is dat endos-
copische herkenning van premaligne afwijkingen moeilijk kan zijn. Daarnaast wordt de 
vaststelling van deze premaligne lesies door middel van willekeurige biopten bemoei-
lijkt door ‘sampling error’ en door de intra- en interobserver variatie bij histologische 
beoordeling. Nieuwe ontwikkelingen op het gebied van zowel endoscopie technieken 
als van weefsel verzameling kan de vaststelling van hooggradige dysplasie en vroeg 
carcinomen verbeteren. Daarnaast kunnen de aanwezige genetische veranderingen in 
metaplastisch en dysplastisch Barrett’s epitheel in de toekomst gebruikt worden voor 
de surveillance van patiënten met een Barrett’s slokdarm, aangezien deze moleculaire 
markers een categorie patiënten kan identificeren met een verhoogd risico op maligne 
ontaarding. Zo hebben bijvoorbeeld patiënten met een verhoogd aantal tetraploïde 
of aneuploïde celpopulaties in Barrett’s epitheel, een verhoogd risico op het ontwik-
kelen van een invasief carcinoom gedurende follow-up (RR 7.5). Voor patiënten met 
Barrett’s metaplasie is het voorkomen van slokdarmkanker een belangrijk doel. Of het 
onderdrukken van de ontstekingsverschijnselen en de zure en gallige reflux een kosten 
effectieve en makkelijk toepasbare behandeling is wordt op dit moment onderzocht in 
de AspECT studie. In deze fase 3 studie worden patiënten met een Barrett’s oesofagus 
met een grootte van 3 cm of meer gerandomiseerd tussen continue lage of hoge dosis 
proton pomp remming met of zonder aspirine. 
Ontwikkeling van nieuwe diagnostische strategieën
Zelfs na een in opzet curatieve operatie, blijft de overleving van patiënten met slok-
darmkanker slecht. Het identificeren van die patiënten die wel of niet kunnen profiteren 
van een operatie is daarom uitermate belangrijk. Positron emissie tomografie (PET) is 
een belangrijk diagnostische middel geworden bij het niet-kleincellig longcarcinoom 
voor de detectie van mediastinale lymfklieren en metastasen op afstand. De waarde 
van een PET-scan om een betere selectie voor een curatieve operatie van patiënten met 
slokdarmkanker te krijgen, is beperkt als patiënten adequaat gestadiëerd zijn. Aan de 
andere kant kan een PET-scan wel een waardevol diagnostisch instrument zijn voor een 
accurate voorspelling van respons op chemoradiotherapie vroeg in de behandeling. Er 
zijn aanwijzigen dat de metabole veranderingen in tumorweefsel, zoals die gemeten 
worden met een FDG-PET scan, de respons beter voorspellen dan een endo-echografie 
of een CT-scan. Of een PET-scan vroeg in de behandeling het niet responderen op neo-
adjuvante chemoradiotherapie kan voorspellen in patiënten met mogelijk curabel slok-
darmkanker, wordt op dit moment onderzocht in de NEOPEC-studie in de neoadjuvante 
arm van een Nederlandse multicenter studie die neoadjuvante chemoradiotherapie 
gevolgd door chirurgie vergelijkt met chirurgie alleen (zie hieronder). 
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Het stadium volgens de TNM classificatie is één van de meest belangrijke prognostische 
factoren voor patiënten met slokdarmkanker. Lagarde et al. toonden aan dat naast de 
TNM stagering ook het aantal positieve lymfklieren of de positieve/negatieve lymfklier 
ratio, extracapsulaire uitbreiding van lymfklieren, de radicaliteit van de slokdarmresectie 
en de tumor grootte belangrijke prognostische factoren zijn. Bij sommige andere tumor 
types spelen de aanwezigheid van prognostische factoren een rol in de beslissingen om-
trent de vervolgbehandeling, zoals adjuvante chemotherapie in het geval van positieve 
lymfklieren bij borst- en dikke darmkanker of de start van palliatieve chemotherapie in 
het geval van een hoge PSA verdubbelingtijd in prostaatkanker. Voor slokdarmkanker 
zijn er nog geen behandeling consequenties verbonden aan de aanwezigheid van prog-
nostische factoren. Echter, de moleculaire pathologie heft een aantal genen en molecu-
len ontdekt, die gerelateerd zijn aan tumor invasie en de ontwikkeling van metastasen. 
Op die manier zijn zij ook gerelateerd aan de prognose. In patiënten met borstkanker 
is de overexpressie van het HER2/neu eiwit geassocieerd met een agressief gedrag van 
de tumor. Trastuzumab, een gehumaniseerd monoklonaal antilichaam tegen het ex-
tracellulaire domein van HER2, is effectief in patiënten met HER2-positiev borstkanker. 
Voor het adenocarcinoom van de slokdarm zijn verschillende prognostische factoren 
van genen en moleculen vastgesteld, zoals HER2/neu, TGF-β, p53, COX2, E-cadherin, 
β-catenin, UPA, MMP-1, DNA aneuploïdie, en >50% promotor hypermethylatie. Gerichte 
therapie tegen deze ‘pathways’ kan het therapeutische arsenaal voor patiënten met dit 
soort kanker vergroten.
Onlangs is het mogelijk gebleken om betrouwbaar circulerende tumor cellen (CTCs) 
te detecteren, te tellen en te karakteriseren. Mogelijke toepassingen hiervan zijn: het 
vaststellen van de prognose, het dienen als een marker om behandeling geïnduceerde 
antitumor activiteit te meten, het detecteren van recidief ziekte, het ophelderen van 
prognostische en predictieve factoren en het onderzoeken van biologische processen 
(disseminatie, geneesmiddelen resistentie, en therapie geïnduceerde celdood). Waar-
schijnlijk zal de detectie, het tellen en de karakterisatie van CTCs op korte termijn een 
waardevolle aanvulling zijn binnen de medische oncologie in termen van onderzoek en 
patiëntenzorg.
Ontwikkeling van nieuwe therapeutische mogelijkheden
Slokdarmoperaties kennen een aanzienlijke peri-operatieve morbiditeit en mortaliteit, 
voornamelijk in ziekenhuizen waar weinig van dit soort operaties worden uitgevoerd. 
Het concentreren van slokdarmoperaties in zogenaamd hoog-volume ziekenhuizen 
kan een positief effect hebben of de morbiditeit en mortaliteit. Een andere belangrijke 
reden om de behandeling van patiënten met slokdarmkanker te centraliseren is de 
aanwezigheid van multidisciplinaire consultatieve teams in de meeste van deze hoog-
volume ziekenhuizen. 
Een conclusie aangaande neoadjuvante chemoradiotherapie van het review artikel in 
dit proefschrift was dat de rol van preoperatieve chemoradiatie nog steeds onduidelijk 
is. Recent is er een meta-analyse gepubliceerd die een significant 2-jaars overlevings-
voordeel liet zien voor preoperatieve chemoradiotherapie en, in mindere mate, voor 
preoperatieve chemotherapie in patiënten met slokdarmkanker. Aangezien deze meta-
analyse gebaseerd is op voornamelijk inadequaat uitgevoerde en kleine fase 3 studies, 
is de waarde van de conclusies van zulke meta-analyses twijfelachtig. Het concept van 
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neoadjuvante chemoradiotherapie blijft echter aantrekkelijk. Om deze reden en van-
wege de gunstige resultaten van onze fase 2 studie met neoadjuvant carboplatin en 
paclitaxel concurrent met radiotherapie gevolgd door een slokdarmresectie, doet ons 
centrum op dit moment mee aan een gerandomiseerde fase 3 studie met dit preopera-
tieve chemoradiotherapie schema gevolgd door operatie versus operatie alleen. Deze 
studie heeft tot op heden meer dan 300 patiënten geïncludeerd.
Er blijven nog veel vragen omtrent de optimale dosering voor bestraling, het bestra-
lings- en chemotherapieschema. Met het gebruik van nieuwe chemotherapeutische 
middelen, zoals taxanen en irinotecan, wekelijks of continue toediening van chemo-
therapie tegelijk met radiotherapie, gehyperfractioneerde radiotherapie schema’s, kun-
nen mogelijk betere behandelresultaten worden geboekt. ‘Targeted therapy’ met een 
cyclooxygenase -2 remmer, ‘vascular endothelial growth factor’ remmers, ‘epidermal 
growth factor’ receptor blokkers of remmers van de ‘mammalian target of rapamycin’ 
zijn aantrekkelijke benaderingen om met radiotherapie of chemotherapie alleen te 
combineren of met chemoradiotherapie.
Zoals gezegd, gaat een slokdarmresectie gepaard met een aanzienlijke peri-operatieve 
morbiditeit en mortaliteit. Naast de forse lichamelijk gevolgen heeft een slokdarmre-
sectie ook grote psychologische en sociale effecten. Een alternatieve, orgaansparende 
behandeling bestaande uit het continueren van de chemoradiotherapie bij patiënten 
die responderen op preoperatieve chemoradiatie is een aantrekkelijke behandeloptie, 
omdat je op die manier een onnodige aanvullende operatie vermijdt. De behandel-
strategie lijkt een geschikte behandeloptie te zijn met een overleving die vergelijkbaar 
is met de overleving na een operatie volgens twee studies, alhoewel in de groep die 
behandeld was met definitieve chemoradiotherapie meer locale recidieven optraden. 
Er zijn dan echter wel geschikte selectie criteria nodig om de patiënten die zullen res-
ponderen op de chemoradiotherapie te identificeren. Op die manier kun je het the-
rapeutische voordeel zo groot mogelijk maken en de toxiciteit zo klein mogelijk. Om 
onnodige toxiciteit te voorkomen, zou het zelf beter zijn om de respons op chemo-
radiotherapie voor start van de behandeling te voorspellen. Verschillende moleculaire 
markers zijn getest op de mogelijkheid om respons op therapie te voorspellen. In een 
studie werd een verband gevonden tussen de respons van patiënten met een Barrett’s 
adenocarcinoma op neoadjuvante chemotherapie met 5-fluorouracil and cisplatin en 
de expressie van methylenetetrahydrofolate reductase (MTHFR), caldesmon (actinomy-
osin regulatory protein), en multidrug resistance protein 1 (MRP1), met sensitiviteit van 
>90%. Meer onderzoek is nodig om diagnostische hulpmiddelen te ontwikkelen die 
de respons op preoperatieve chemoradiotherapie kunnen voorspellen door middel van 
het analyseren van de biopten die uit het tumorweefsel genomen zijn.
Het effect van een slokdarmresectie met of zonder preoperatieve behandeling op de 
kwaliteit van leven van patiënten met slokdarmkanker wordt vaak onderbelicht. Omdat 
gezondheid gerelateerde kwaliteit van leven beoordeling extra informatie geeft over de 
toxiciteit van een chemoradiotherapie schema, en om de mogelijke gevolgen van neo-
adjuvante chemoradiotherapie op een verminderd of vertraagd herstel van gezondheid 
gerelateerde kwaliteit van leven na een slokdarmresectie te beoordelen, wordt ook een 
kwaliteit van leven onderzoek uitgevoerd in de boven genoemde fase 3 studie. De re-
sultaten van die studie kunnen gebruikt worden om patiënten te informeren over zij 
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kunnen verwachten van deze ‘multimodality’ behandeling en op die manier kunnen de 
resultaten bijdragen in het proces van het kiezen voor een behandeling door behande-
laar en patiënt.
Voor de vele patiënten met gemetastaseerde of gerecidiveerde slokdarmkanker zijn 
geen curatieve behandelmogelijkheden voorhanden. Voor deze patiënten is palliatie 
van dysfagie en van andere symptomen zoals pijn en vermoeidheid zeer belangrijk. 
Juist in deze groep patiënten is het verbeteren of het behouden van kwaliteit van le-
ven zeer belangrijk. Echter, op dit moment zijn de standaarden voor het analyseren van 
kwaliteit van leven en van symptoom controle in gerandomiseerde. Het definiëren van 
een palliatief eindpunt, met een a-priori hypothese, is essentieel; het is gewenst het 
aantal patiënten met palliatieve response te definiëren. Een ‘checklist’ kan behulpzaam 
zijn om de standaarden van toekomstige gerandomiseerde studies te vergroten.
Het plaatsen van een ‘self-expanding’ metalen stent, uitwendige radiotherapie, intralu-
minale radiotherapie (brachytherapie), en laser therapie zijn vaak gebruikte palliatieve 
mogelijkheden om dysfagie te behandelen. Er zijn maar weinig studies verricht die deze 
behandel mogelijkheden met elkaar vergelijken. Er zijn geen studies die het effect van 
chemotherapie vergelijken met het effect van andere palliatieve behandelingen op 
symptoomcontrole (bijvoorbeeld dysfagie). In een studie is het gebruik van ‘single-dose’ 
brachytherapie vergeleken met het plaatsen van een metalen stent ter palliatie van dys-
fagie in patiënten met slokdarmkanker. Ondanks langzame verbetering gaf ‘single-dose’ 
brachytherapie betere lange termijn verbetering van dysfagie dan plaatsing van een 
metalen stent. Aangezien brachytherapie gepaard ging met minder complicaties dan 
stent plaatsing en aangezien, nog belangrijker, het effect van ‘single dose’  brachythera-
pie op gezondheid gerelateerde kwaliteit van leven gunstiger is dan van stent plaatsing 
voor de palliatie van slokdarmkanker, wordt ‘single-dose’ brachytherapie aanbevoelen 
als eerste behandeling van dysfagie ten gevolge van slokdarmkanker.
De resultaten van de fase 2 studie die het effect van de behandeling met oxaliplatin en 
capecitabine van patiënten met gemetastaseerd of lokaal vergevorderd slokdarmkanker 
onderzocht in dit proefschrift, toonden aan dat palliatieve chemotherapie in staat is om 
de kwaliteit van leven gedurende de behandeling kan behouden en mogelijk zelfs symp-
tomen kan verlichten (pijn). Het effect van chemotherapie op overleving is onduidelijk, 
voornamelijk ten gevolge van het gebrek aan gerandomiseerde studies. De conclusies 
van de Cochrane Review betreffende het gebruik van chemotherapie bij patiënten met 
gemetastaseerde slokdarmkanker of kanker van de slokdarm-maagovergang zijn dat er 
een grote behoefte is aan goed uitgevoerde fase 3 studies van voldoende grootte die che-
motherapie vergelijken met goede palliatieve zorg bij patiënten met gemetastaseerde 
slokdarmkanker. Cytostatica met mogelijke goede respons percentages en acceptabele 
toxiciteit zijn cisplatin, 5-fluorouracil (5-FU), paclitaxel en antracyclines. Toekomstige stu-
dies die palliatieve behandel mogelijkheden vergelijken moeten ook kwaliteit van leven 
beoordelen met behulp van gevalideerde kwaliteit van leven vragenlijsten.
De toegenomen kennis van de moleculaire biologie van kanker en de ontwikkeling van 
nieuwe diagnostische mogelijkheden en ‘targeted’ middelen bieden nieuwe uitdagin-
gen en kansen voor de behandeling van patiënten met slokdarmkanker en de ontwik-
keling van meer therapie op maat met het beste resultaat voor onze patiënten.
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En dan na vier jaar is het zover, het boekje is af! Dit heeft alleen kunnen gebeuren door 
hulp van velen, zowel op wetenschappelijk als op sociaal niveau. Graag zou ik iedereen 
hier persoonlijk voor bedanken, maar ook voor het dankwoord geldt een woordenli-
miet. Zonder anderen tekort te willen doen, wil ik een aantal personen in het bijzonder 
bedanken, zonder hen was dit proefschrift nooit tot stand gekomen.
Zonder patiënten geen patiëntgebonden onderzoek
Grote dank ben ik verschuldigd aan de patiënten die hun medewerking hebben hebben 
verleend aan de in dit proefschrift beschreven onderzoeken en aan alle andere onder-
zoeken, waardoor we stap voor stap dichter bij een betere behandeling van kanker kun-
nen komen. Zij waren/zijn bereid om buiten de routine bezoeken aan het ziekenhuis 
om, extra onderzoeken en niet-standaard behandelingen te ondergaan en ellenlange 
vragenlijsten in te vullen.
Zonder promotiecommissie geen promotie
Op de eerste plaats wil ik mijn copromotor, dr. A. van der Gaast, bedanken. Beste Ate, 
dank voor je zeer prettige, soms zelf bijna vaderlijke, begeleiding bij het tot stand ko-
men van dit proefschrift. Ik heb dat altijd zeer gewaardeerd. Dank voor je geduld en je 
vertrouwen dat het toch wel af ging komen. Je accepteerde mijn hang aan het sociale 
leven, maar wist me op een subtiele manier toch altijd weer er op te wijzen dat het weer 
eens tijd werd voor de wetenschap. Van je gestructureerde correcties van de manus-
cripten heb ik veel geleerd. Zo ook van je uitgebreide kennis van het vak oncologie, niet 
alleen op internistisch gebied! Dank voor alle mogelijkheden die je me geboden hebt!
Mijn promotor, prof. dr. J. Verweij. Beste Jaap, dank voor het vertrouwen dat je in me ge-
steld hebt en dat je het stokje een half jaar geleden van Gerrit hebt willen overnemen. Er 
restten toen voornamelijk organisatorische taken, maar daar zat je dan ook bovenop! Ik 
ben benieuwd hoe mijn promotietraject er zou hebben uitgezien als je vanaf het begin 
mijn promotor was geweest! Je positief kritische beoordeling van de introductie en de 
samenvatting heb ik in ieder geval zeer gewaardeerd.
De secretaris van de promotiecommissie, prof. dr. H.W.G. Tilanus. Beste Huug, dank voor 
het op je nemen van deze taak, voor de beoordeling van dit proefschrift en de diverse 
artikelen, en voor de bezielende leiding over de Rotterdamse slokdarm werkgroep.
Dr. H. van Dekken, lid van de kleine commissie, ben ik eveneens veel dank verschul-
digd. Beste Herman, dank dat je zitting hebt willen nemen in de commissie, ondanks 
je vertrek uit het prachtige Rotterdam naar 020. Dank ook voor de beoordeling van de 
vele slokdarmbiopten en resectiepreparaten voor het “PA-stuk” en voor je geduldige 
begeleiding bij het schrijven hiervan. Ik wens je veel succes bij het opzetten van de 
opleiding pathologie in het Lucas Andreas.
Prof. dr. E.E. Voest dank ik voor het de snelle beoordeling van het manuscript en bereid-
heid tot plaatsneming in de commissie.
Prof. dr. R.J. Baatenburg de Jong, prof. dr. P.C. Levendag en prof. dr. E.J. Kuipers wil ik 
danken voor het plaatsnemen in de promotiecommissie.
Tevens wil ik dr. M.L. Essink-Bot dank voor het plaatsnemen in de promotiecommissie 
als deskundige op het gebied van kwaliteit van leven onderzoek. Beste Marie-Louise, 
ook jij hebt veel geduld met me moeten hebben. Ik heb de samenwerking met jou altijd 
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als erg prettig ervaren en dank je voor je altijd opbouwende kritiek, dat droeg zeker bij 
aan mijn kwaliteit van leven! Jammer dat je weg bent uit Rotterdam.
Op deze plaats wil ik toch ook nog mijn voormalige promotor bedanken, prof. dr. G. 
Stoter. Beste Gerrit, dank voor de ruimte die je ons aan de overkant van de Maas hebt 
gegeven om dit onderzoek te doen, terwijl je altijd een oogje in het zeil hield. Ook jou 
ben ik dank verschuldigd voor het vertrouwen dat je in me gesteld hebt. Zoals het mijn 
co-promotor niet is gelukt je “eerste” promovendus te zijn, zo is het mij net niet gelukt 
je “laatste” te zijn.
Zonder ondersteuning geen uitvoering van onderzoek
Zonder de ondersteuning van researchverpleegkundigen en datamanagers zou geen 
enkel onderzoek uitgevoerd kunnen worden. In het bijzonder wil ik Leni bedanken voor 
de onvermoeibare inzet bij het verzamelen van alle kwaliteit van leven formulieren. 
Mede hierdoor is het kwaliteit van leven artikel geworden tot wat het is.
Zonder rotterdamse Slokdarm werkgroep geen behandeling van slokdarmkan-
ker
Dank ook aan de Rotterdamse Slokdarmawerkgroep, welke garant staat voor een uit-
stekende samenwerking, waardoor multidisciplinaire behandeling en onderzoek van 
slokdarmkanker mogelijk worden. Ik dank een ieder voor de altijd zeer prettige samen-
werking.
Zonder collega’s geen dokter meertens
Ferry, Maria, Lia, Stefan, Maja, Caroline, Paul, Wim, Karin, André, Agnes, Marijke en Ro-
nald en alle huidige en verleden fellows wil ik bedanken voor de prettige samenwerking 
en de dingen die jullie me leren. In het bijzonder wil ik Stefan bedanken, voor alle hulp 
die je me geeft en voor de kameraadschap (snap je ‘m?).
Op deze plaats wil ik ook Marja van Hoorn bedanken. Je hebt een jaar lang mij fantas-
tisch secretarieel ondersteund. Dank voor al je inzet, met name als ik weer eens opging 
in mijn neurose omtrent de promotie!
Zonder vrienden geen sociaal leven
Lieve vrienden, jullie zijn zo’n belangrijk onderdeel van mijn/ons leven. In het bijzonder 
wil ik “mijn” vriendinnetjes bedanken.
Lieve Meiden, wat zijn jullie mij goud waard. Een vriendschap opgebouwd tijdens kleu-
ter-, lagere en middelbare school, en nog steeds vieren we de verjaardagen, het jaarlijk-
se meidenweekend, volgend jaar weer een lustrumreis en niet te vergeten: Sinterklaas. 
Lieve Sien, Mon, Elies, Klas, Ruig en Ier, dank voor alle onvergetelijke momenten. Ik hoop 
dat er nog vele zullen volgen.
Lieve studievriendinnetjes, Ginny en Monique. Ook onze vriendschap heeft de tand des 
tijds doorstaan, en dat is niet voor niets! Dank voor de onvergetelijke studententijd toen 
en de vriendschap nu.
Lieve Zuidervriendinnetjes, zoals gezegd in Italië ben ik ome Arie zeer dankbaar dat 
hij ons alle 5 heeft aangenomen. Lieve Miek, Ka, Chris en Jo ook jullie dank voor de 
fantastische tijd toen en de vriendschap nu.
Dankwoord   
116
Jo, helaas zul je er waarschijnlijk niet bij zijn, omdat je dan in het kraambed ligt. Geluk-
kig heeft onze vriendschap ook de afstand overleefd. En ach, zo ver is Genève nu ook 
weer niet en nu heb ik nog een extra reden om naar de Alpen te gaan!
Zonder b(r)oer geen zus
Lieve Paul, één jaar geleden was het jouw dag. Na 10 jaar (of waren het er nou 11?) kon 
ook jij je academische titel binnen halen. Ik heb altijd geloofd dat je het zou volbrengen 
en ik ben er dan ook zeer trots op dat het je gelukt is. Heb je je trouwens wel eens gere-
aliseerd dat jij de eerste van ons twee bent met twee titels? 
Zonder ouders geen esther
Lieve papa en mama, jullie ben ik veel dank verschuldigd. Zonder jullie zou ik niet be-
staan. Jullie hebben mij een onbezorgde jeugd en alle kansen van het leven gegeven. 
Altijd hebben jullie mij gesteund in de dingen die ik deed, ook al hadden jullie daar je 
eigen gedachten over. Daarom draag ik dit boekje met liefde aan jullie op.
Zonder paranimfen geen promovendus
Lieve Ka en Ier, mijn paranimfen, wat fijn dat jullie naast me willen staan.
Ka, jij hebt het protocol geschreven voor het fase 2 onderzoek met neoadjuvante 
chemoradiotherapie. Dit is een heel belangrijke basis geweest voor dit proefschrift (3 
artikelen!). Daarnaast ben je mijn soulmate-je. Logisch dus dat je naast me staat, heel 
fijn. Ik zal je missen in de Daniel, maar ook voor onze vriendschap zal de afstand geen 
hindernis zijn.
Ier, van buurmeisje van opa, via klasgenootje en vriendinnetje op de lagere school, via 
vriendinnetje met de Meiden tot paranimf. Onze vriendschap kent een heel bijzondere 
opbouw en is steeds meer gaan betekenen. Fijn om zo’n veilige basis en fijne vriendin 
naast me te hebben deze dag.
Zonder man geen vrouw
Lieve Mario, ik zeg Chamonix en jij weet genoeg. Fly me to the moon…………! DZ, 
Chica.
En nu is het echt af: Hakuna Matata!!!!!!!
Rotterdam, juni 2008
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CurriCulum vitae
Esther van Meerten werd op 27 oktober 1971 geboren te Rotterdam. In 1990 behaalde 
zij haar VWO-gymnasiumdiploma aan de Rijksscholengemeenschap te Oud-Beijerland. 
Aansluitend ging zij geneeskunde studeren aan de Erasmus Universiteit te Rotterdam. 
In december 1997 behaalde zij haar artsexamen met lof. Zij werkte in 1998 als AGNIO 
interne geneeskunde in het voormalige Zuiderziekenhuis (tegenwoordig Medisch 
Centrum Rijnmond Zuid, locatie Zuider). In januari 1999 startte zij met de opleiding tot 
internist in datzelfde ziekenhuis (opleider dr. A. Berghout). Vanaf januari 2003 werd de 
opleiding voortgezet in het Erasmus MC (opleider prof.dr. H.A.P. Pols). In januari 2004 
startte zij met de opleiding voor het aandachtsgebied interne oncologie (opleider prof.
dr. G. Stoter) op de centrumlocatie van ditzelfde ziekenhuis. In de zomer van 2004 be-
gon zij aan de onderzoeken die werden beschreven in dit proefschrift. Vanaf september 
2006 is zij werkzaam als staflid van de afdeling interne oncologie op de locatie Daniel, 
sinds jaunari 2008 in vast dienstverband.
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